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SUMMARY 
Despite remarkable progress in understanding biology and disease at the level of 
nucleic acids, insights into the relevant biochemical processes frequently remain 
preliminary, since much regulation and activity occurs at the protein level through 
control of gene expression and variations of protein conformation. In particular, the 
effect of such variations on protein interactions is critical for a better description of 
biology and disease. Protein microarray technology provides a means to such ends and 
is a growing field of proteomics, with a high potential for analytical and functional 
applications in biology and medicine. On the basis of sequence information from 
individuals, it is possible to characterize disease-specific protein isoforms that result 
from mutations, polymorphisms, and splice variants with personalized protein 
microarrays. During my thesis, I developed such a technique. 
As a first step, solid-phase PCR is applied to copy a particular tissue’s 
RNA/cDNA onto the microarray surface, using for each gene a specific primer pair that 
is attached to the chip surface. The generated DNA templates are firmly attached to and 
specifically oriented on the array surface. The solid-phase PCR successfully amplified 
DNA of up to 3 kb, also allowing multiplex amplification of DNA. The arrayed DNA 
copies then act as templates for an in situ cell-free expression, yielding a protein 
microarray that presents the protein content of a particular tissue of an individual 
person. Expression control was conducted by a multiple spotting technique (MIST). 
C-terminus detection showed that translation was complete, yielding full-length 
proteins.  
During the process of setting up the technique of producing individualized protein 
microarrays, the MIST technology was optimized concomitantly. The various steps 
involved were analyzed to determine optimal conditions for template preparation, 
protein expression and interaction detection. Protein microarrays of 3500 human 
proteins were produced with these procedures and their performance was tested in 
model studies of protein–protein interactions. 
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ZUSAMMENFASSUNG 
Trotz erheblicher Fortschritte im biologischen Verständnis funktioneller, zellulärer 
Abläufe sowie der entsprechenden krankheitsrelevanten Störungen auf der molekularen 
Ebene der Nukleinsäuren, sind viele zugrunde liegende biochemische Prozesse häufig 
nur in Grundzügen oder teilweise bekannt, da ein Gutteil der Aktivität und Regulation 
durch Proteine, etwa durch Variation ihrer Expression oder ihrer Konformation, erfolgt 
oder beeinflusst wird. Speziell eine bessere Kenntnis der Effekte dieser Änderungen auf 
Proteinwechselwirkungen ist von elementarer Bedeutung für ein tieferes Verständnis 
biologischer Zusammenhänge und krankheitsrelevanter Störungen. Protein-Microarrays 
ermöglichen ebensolche Untersuchungen und sind eine wichtige Schlüsseltechnologie 
für das sich rasant entwickelnde Feld der Proteomik, mit einem großen Potenzial für 
analytische und funktionale Untersuchungen in Biologie und Medizin. Aufgrund 
vorhandener Sequenzinformationen von Einzelpersonen ist es nun möglich, krankheits-
spezifische Proteinisoformen, die auf Mutationen, Polymorphismen, und Splice-
varianten basieren, mittels personalisierter Protein-Microarrays zu charakterisieren. Im 
Rahmen der vorliegenden Doktorarbeit wurde ein solches Verfahren entwickelt und 
ausführlich erprobt. 
Im ersten Schritt wird per Festphasen-PCR die RNA/cDNA eines Gewebes auf 
eine Microarray-Oberfläche kopiert. Dies geschieht für jedes Gen mit einem 
spezifischen Primer-Paar, das vorher an der Chip-Oberfläche befestigt wurde. Die 
entstehenden cDNA-Segmente sind auf der Array-Oberfläche lokalisiert und orientiert. 
Die Festphasen-PCR kann DNA bis zu einer Größe von 3 kb erfolgreich vervielfältigen; 
Multiplex-Amplifikation der DNA ist ebenfalls möglich. Die cDNA-Kopien auf dem 
Microarray dienen als Vorlage für eine zellfreie Expression in situ. Hierdurch entsteht 
ein Protein-Microarray, der das gewebespezifische Proteinmuster einer einzelnen 
Person widerspiegelt. Die Expressionskontrolle wurde mit der Multiple-Spotting 
Methode (MIST) gewährleistet. C-Terminus-Erkennung diente als Nachweis für die 
abgeschlossene Translation mit entsprechend vollständigen Proteinprodukten. 
Im Zuge der Entwicklung der personalisierten Protein-Microarrays wurde 
gleichzeitig das MIST-Verfahren weiter optimiert. Die einzelnen Arbeitsschritte wurden 
verbessert in Bezug auf bestmögliche Ergebnisse der Herstellung der DNA-Vorlage, der 
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Protein-Expression sowie der Erkennung von Protein–Protein Wechselwirkungen. 
Protein-Microarrays mit 3500 Humanproteinen wurden mit den neu entwickelten 
Verfahrensschritten hergestellt und in Pilotstudien auf ihre Aussagekraft in Bezug auf 
Protein–Protein Wechselwirkungen hin geprüft. 
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1 INTRODUCTION 
The deciphering of the human genome has provided the basic sequential information 
contained in the DNA, but there is still the need of elucidating the corresponding 
functional and mechanistic details of cellular processes leading up to an understanding 
of molecular interrelationships within the cells [1,2]. The response of individual cells 
to extracellular signals and the way cells associate in multicellular organisms can be 
understood by defining the activities of individual proteins. Each protein is involved in 
many interactions with other proteins as well as with nucleic acids, phospholipids, 
carbohydrates, and small ligand molecules [3]. As part of a complex system, a protein 
is not a solo actor. Protein complexes are established by stable or transient physical 
contacts forming large networks of interactomes controlling all cellular functions [4]. 
The development of high-throughput proteomics on the basis of protein 
microarrays is technically demanding due to the structural diversity and complexity of 
proteins (Fig. 1). Protein microarrays contain hundreds to thousands of different protein 
molecules that can be used for profiling analyses and functional screening. 
 
Figure 1. Protein microarrays. (a) Functional protein microarrays for studying protein 
interactions. A number of proteins or peptides are purified or synthesized, then 
immobilized onto a surface. The arrays are used to investigate protein interactions, for 
identifying the substrates of enzymes, and for studying post-translational modifications.  
(b) Analytical protein microarrays, represented by dual-color antibody arrays. Different 
types of capture molecules such as antibodies, aptamers, or antigens with high affinity and 
specificity are arrayed onto a surface. The procedure can be used to monitor expression 
levels and profiling of proteins from sample and reference. 
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Profiling protein microarrays are based on immobilized specific proteins such as 
antibodies that can recognize particular proteins from a sample mixture [5].  
Functional protein microarrays contain entire proteins or protein domains that can 
be used to identify or screen for interactions with proteins, peptides, nucleic acids, and 
various types of smaller ligands [6]. To date, protein microarrays are mostly produced 
by spotting purified proteins onto solid surfaces [7]. Alternatively, protein arrays can be 
produced by using cell-free expression systems. Although most of the newly 
synthesized proteins do not retain their native three-dimensional structure, many 
binding sites will be of sufficient quality for individual applications. Cell-free 
expression systems use cell lysates from growing cells, either prokaryotic or eukaryotic, 
that contain the entire essential components for transcription and translation and can use 
mRNA or DNA as templates [8]. Cell-free-based protein microarrays can avoid the 
bottleneck of protein expression and purification [9,10].  
Several cell-free protein microarray technologies have been developed. Nucleic 
acid programmable protein arrays (NAPPAs) simultaneously spot biotinylated cDNA 
plasmids encoding GST fusion proteins and anti-GST antibodies onto avidin-coated 
slides. In situ expression has been achieved by incubating the spotted molecules with 
cell-free lysate from rabbit reticulocytes. The expressed proteins were captured by anti-
GST antibodies within each spot [10]. In a different strategy, two slides are used in a 
technology called DNA array to protein array (DAPA) – the first slide immobilizes the 
DNA templates, and the second captures the expressed proteins; cell-free lysate is 
placed between the two slides [9]. Another strategy uses the multiple spotting technique 
(MIST) where unpurified PCR products are spotted as DNA templates, followed by 
Escherichia coli-based lysate being placed directly on top of the spotted DNA [11]. 
Protein microarrays containing several hundred human proteins have been designed 
using MIST. 
Alternatively, the attached DNA can be directly synthesized on the slide surface 
using on-chip PCR technology. The technology can be utilized to amplify RNA or 
cDNA encoding disease-specific protein isoforms (mutations, polymorphisms, and 
splice variants) on slide surfaces using DNA-specific primers attached to the slide 
surface. The DNA arrays act as templates for in situ cell-free expression to produce 
protein arrays of particular tissues of an individual person. On-chip PCR has been 
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introduced to synthesize DNA based on the extension of one or two primers covalently 
attached to the surface by DNA polymerase [12,13]. 
Aims and Scope. A new technique was developed to produce personalized protein 
microarrays from surface-bound DNA templates by on-chip PCR. The bound DNA is 
expressed using an in situ cell-free procedure to yield proteins on the array. Also, the 
MIST procedure was employed to produce and optimize protein microarrays of 3500 
human proteins. Array quality was analyzed to determine and evaluate the technical 
usability and variability of the involved PCR, protein expression, and probing. These 
protein microarrays were used in various model studies of protein–protein interactions 
and screened for antibody specificity. 
1.1 From Genomics to Proteomics 
The final human genome sequence was published three years after the first 
announcement of a draft of the human genome in 2001. Smaller tasks still remain to be 
solved until sequencing technologies are able to read the highly repetitive sequences 
within heterochromatin [14]. Revealing the biological functions of 2.85 billion bases of 
the human genome from protein-coding genes, non-protein-coding genes, noncoding 
sequences, and regulatory elements is a key challenge for biomedical research [15,16]. 
The major human gene catalogs are Ensembl, RefSeq, UNSC, and GENCODE− 
each listing about 25,000 protein-encoding genes [17-19]. The ENCODE consortium 
has been able to determine the major biochemical functions of the human genome, 
while 20% of these functions remain unknown. Knowing the complete sequence has 
increased our understanding of the genome and in the near future this knowledge may 
lead to clinical applications. For example, gene expression profiling has provided 
several prognostic signatures in breast cancer (including NKI-70-gene, wound-
response, and stem-cell signatures) [20]. These achievements are supported by high-
throughput genomic analyses that can perform rapid and simultaneous interrogation of 
massive data. 
The number of protein-coding genes in the human genome appears to be lower 
than the complexity of the biological functions of human cells [21]. The lack of 
correlation is explained by the transcriptional control mechanism of the regulating 
differential gene expression. Alternative transcripts and splicing hence generate 
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multiple transcript variants that may encode functionally distinct protein isoforms in 
addition to a diversity of structure modifications during protein synthesis [22-25]. 
1.1.1  Proteomic Diversity 
Following high-throughput genomic analysis, correlations of mRNA expression levels 
and protein abundance can be surveyed [16]; such studies have been carried out in 
multicellular organisms [26]; larger proteomic datasets in progress may eventually 
provide the means for more detailed correlation studies. One study in the human Daoy 
medulloblastoma cell line found that mRNA expression only related to about 66% of 
the determined protein abundance and variation [27]. The diverse control mechanisms 
involved in production and maintenance of cellular proteins likely serve to provide a 
broad range of functional variability. Alternative splicing and protein modification 
contribute to this variability. Post-transcriptional, post-translational, and degradation 
mechanisms and their role in regulating protein abundance are still only barely 
understood [28-31]. Transcriptional control mechanisms regulate differential gene 
expression, alternative transcripts, and splicing thereby generating multiple transcript 
variants that encode functionally distinct protein isoforms [23,24,32]. 
Alternative splicing appears to serve to increase protein diversity thus enabling to 
manage the working machinery in multicellular eukaryotes without significantly 
increasing the genome size [29,33]. The mechanisms can be categorized based on five 
basic splicing patterns: casssete exons, alternative 5′ splice sites, alternative 3′ splice 
sites, mutually exclusive exons, and retained introns [34]. Furthermore, alternative 
splicing not only increases proteome size but contributes to the complexity of signaling 
and regulatory networks of higher organisms [28]. It has been estimated that between 
35% and 60% of protein isoforms are derived from alternative splicing of mRNA [34]. 
The importance of alternative splicing as a regulatory process has become notably 
evident through its common occurrence regarding pre-mRNAs of regulatory and 
signaling proteins [35]. Alternative splicing can augment organism complexity, not only 
by effectively increasing proteome size and regulatory and signaling network 
complexity, but also by doing so in a time- and tissue-specific manner. Therefore, the 
mechanism can support cell differentiation, developmental pathways, and other 
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processes associated with multicellular organisms [35,36]. Alternative splicing has been 
proposed to occur in respect to intrinsic disorders [37]. 
There are examples of every kind of splicing in cancerous cells. Splice events that 
affect the protein-coding region of mRNAs lead to proteins that differ in their sequence 
and activities; splicing within the noncoding regions can result in changes in regulatory 
elements, such as translation enhancers or RNA stability domains, which may 
dramatically influence protein expression [34]. Cancer-specific splicing events have 
been reported in colon, bladder, pancreatic, and prostate tissue with diagnostic and 
prognostic implications [38,39]. Combined studies have utilized a spliceoform-specific 
microarray and PCR to evaluate all known splice variants in human pancreatic cancer 
cell lines representing a spectrum of differentiation, from near-normal HPDE6 to 
Capan-1 and poorly differentiated MiaPaCa2 cells. Data from both cell lines and human 
pancreatic tissue has revealed the largest diversity in alternative spliceoforms in normal 
cells and tissues, while pancreatic cancer and cancer cell lines showed a sharp reduction 
in the number of spliceoforms [40]. Therefore, proteome studies aiming to elucidate 
protein structures, functions, and interactions may very well lead to a better 
understanding of the biological functions of individual genes. 
1.1.2  Protein–Protein Interactions (PPIs) 
The identification of each protein and mapping of its interactions with stable or 
transiently interacting protein partner(s) will help us to better understand biological 
functions in the context of protein cellular networks [41]. The complete interactome 
approach has provided a valuable fundamental understanding of biological system 
network dynamics, and has helped in identifying relevant information on drug targets 
for applied biomedical research. This understanding of signaling protein interactions 
has allowed to elucidate certain cancer-related processes, like signaling, cell cycle 
control, and DNA repair mechanisms. The mapping of the human interactome as a 
complete network from both healthy and cancer patients can significantly help to 
identify potential drug targets [3, 42-44]. 
Around 130,000 binary interactions were estimated in the human interactome 
using a Monte Carlo simulation based on a combination of experimental data of high-
throughput yeast two-hybrid system (Y2H), mammalian reverse two-hybrid technology 
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(MAPPIT), and Bayesian modeling [45]. Similarly, the combination of Y2H and small 
interference RNAs has been successful to map 2,269 protein interactions involved in 
the mitogen-activated protein kinase (MAPK) pathway, known as one of the main 
pillars of signal transduction in the mammalian cell [46]. Moreover, the statistical 
estimation could generate 4,000 types of complex proteins, but the protein structures 
available in the protein databank (PDB) at this time only covered 42% of the predicted 
protein complexes. This study also predicted that another 25 years of experimental 
work was needed to complete the repository [47]. Therefore, open-source human 
protein–protein interaction (PPI) databases have become a major resource for 
investigating cellular protein networks and signaling pathways. The Agile Protein 
Interaction DataAnalyzer (APID) has integrated the experimentally validated human 
interactome databases such as BIND, BioGRID, DIP, HPRD, IntAct, and MINT into a 
single interactive bioinformatic web tool [48]. 
PPI studies have revealed several effects that one interacting partner has over the 
other one – like, altering the kinetic properties of proteins, formation of new binding 
sites, change in the specificity of a protein for its substrate, and possible inactivation of 
a protein [49]. The interactions between proteins can occur in a transient or more 
permanent manner. Transient interactions are far less conserved and colocalized than 
stable interactions. They are the dominating players in cell processes and include 
several protein families like kinases, phosphatases, glycosyl transferases, and proteases, 
amongst others. They are involved in the recruitment and assembly of the transcription 
complex to specific promoters, the transport of proteins across membranes and 
breakdown and reformation of subcellular structures like the spindle apparatus and the 
nuclear pore complex during cell division [41]. Protein interactions can be obligate, 
where a protein constitutes an integral part of the structure (e.g., hemoglobin, 
ribosomes, and proteasomes) or nonobligate, where each individual component of a 
complex can exist free in solution [50]. However, there is no clear distinction between 
obligate and nonobligate interactions, rather there exists a continuum between them 
which depends on their physical localization and on various conditions like pH, protein 
concentration, etc. 
Understanding the recognition events of PPIs requires the description of the 
binding thermodynamics that manage the associations under equilibrium conditions: the 
free energy and entropy of the binding and enthalpy of individual proteins involved in 
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the protein complex [51]. The strength of the PPI is defined by the dissociation constant 
(Kd) or as the affinity constant (Ka) which is the inverted value of Kd that is commonly 
employed for characterizing antibody–antigen interactions [50]. The Kd value needs to 
be specifically defined and be independent of the method used to measure it. Numerous 
proteomics methods have been used to provide thermodynamics data, kinetic analyses, 
and stoichiometric information [52-54]. We concisely describe the methods that have 
been commonly used to identify PPIs followed by description of several analyses 
regarding characteristic interactions studied in this project. 
The methods were developed with different consideration related to the nature of 
the proteins and the type of PPIs. Instead of only finding single protein pairs, co-
complex methods like co-immunoprecipitation (Co-IP) and affinity purification (AP) 
have the potential to catch sets of proteins and decipher the result as part of a protein 
network [55,56]. With the advantage of high-throughput performance and easy 
multiplexing, array-based technology is an attractive choice to detect PPIs attached to a 
surface. Furthermore, the protein microarray technology allows for high-throughput 
detection of PPIs and source protein bottlenecks can be avoided by the reduced labor 
input of cell-free protein expression system [5,7,57]. Ionization and separation of 
mass/charge ratios by mass spectrometry (MS) has advantageously been introduced to 
proteomics studies. As a golden method in proteomics, MS can be used both to identify 
protein modification (phosphoproteome) and for large-scale quantification of proteins 
(quantitative proteomics). MS-based quantitative proteomics can be applied for relative 
and absolute quantification [58]. 
Microscopic techniques have recently been employed to detect intact intracellular 
PPIs also providing useful information regarding their colocalization, especially 
through Förster or fluorescence resonance energy transfer (FRET), bimolecular 
fluorescence complementation (BiFC), and fluorescence correlation spectroscopy (FCS) 
[59-61]. These provide means for directly observing as to how, where, and when  
a protein interacts under natural conditions and natural expression levels without 
altering the physiological state of the cell. These techniques rely on the spectral 
emission from fluorescent and chemiluminiscent molecules that are either fused or 
conjugated [59,60]. The dye molecules can be combined with chemical and photo-
crosslinking techniques, such as proximity-induced ligation or the recent protein 
complementation assay (PCA) [62]. 
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1.2 Protein Microarrays 
The emergence of protein microarrays followed in the footsteps of DNA microarrays. 
The basic concept of protein microarrays (Fig. 1) was first developed on the basis of the 
immunoassay concept scaling down the assay into micro-spot size [63]. This offers the 
advantage for a rapid, easily multiplexed, high-throughput procedure and only requires 
very small volumes of sample consumption over other proteomics methods. Depending 
on the mode of application, there are two different types of protein arrays: analytical 
and functional. The analytical protein microarray is still in an early stage of 
development and is based on binding molecules such as antibodies, antigens, or 
aptamers. These capture molecules are designed to specifically recognize particular 
proteins from complex mixtures of samples [64].  
Antibody microarrays are most commonly employed in multiplexed high-
throughput studies in cancer proteomics research. The development of detection 
methods for antibody microarrays has become a major challenge in particular regarding 
their sensitivity and reliable performance for future use as diagnostic tools [65]. 
Although ELISA-like traditional sandwich assays can be applied for antibody 
microarrays, the most common methods for detecting interacting proteins are by 
chemically labelled proteins from test and reference samples (healthy or cancerous) 
with two different fluorophores (e.g., Cy3 and Cy5). Antibody microarrays can provide 
profiles from protein extracts and from cell culture supernatants, protein extracts of 
tissue specimens, and from body fluids [66-68]. For comparing cancerous and normal 
cells, antibody microarrays can be used to identify cancer-specific biomarker 
candidates, to characterize the protein profiles, and to identify differentially expressed 
proteins associated with disease progression. The second type of protein microarrays 
will be discussed in more detail in the following section. 
1.2.1 Functional Protein Microarrays 
Functional protein microarrays are constructed by immobilizing a large number of 
individually purified proteins or protein domains onto a solid support, typically a glass 
surface, and are utilized for identifying the biochemical properties and the activity of 
the arrayed proteins. Functional protein microarrays (mostly just named protein 
microarrays) have been used to recognize protein–protein [12,69,70], protein–antibody 
INTRODUCTION 
 
9 
 
[64,71,72], protein–DNA, protein–RNA, protein–small molecules interactions [73], and 
for studying protein kinase substrates [2,5]. With this technology platform, one can 
easily examine the entire proteome by using cDNA from any biological source of 
interest. Having this potential, proteome arrays have developed rapidly within the last 
few years in the direction of obtaining biologically active protein arrays. 
 In the early stage, protein arrays were constructed as printed individually purified 
proteins that were expressed in E. coli or yeast by using contact or non-contact spotters 
[7,12]. One of this type of protein arrays has been used to print thousands of purified 
proteins for studying protein–protein interactions, kinase substrate identification, and to 
identify the small molecule-targeting proteins [7]. Another type of spotted protein array 
contained 82 purified coronavirus proteins expressed in yeast, purified by GST tags and 
spotted onto FAST slides, and then used to screen sera from patients with severe acute 
respiratory syndrome (SARS) infection and healthy controls [74]. However, using the 
traditional method for obtaining individual purified proteins by overexpression in host 
cells has some obvious limitations, such as toxicity, inhibitory effects, and low 
solubility of proteins. A further disadvantage of this process is the fact that it can take 
up to three weeks of labor-intensive work from expression to purification and finally 
spotting the proteins into an array [74]. 
In situ cell-free protein expression has helped to overcome this problem where the 
major bottleneck has been lessened with the labor and cost effective production of 
proteins of interest [5,57]. Moreover, cell-free expression systems from E. coli, wheat 
germ, insect and rabbit reticulocytes are rapidly gaining popularity with their clear 
benefit for protein expression over in vivo expression using living cells [75]. Thus, 
problems can be eliminated that are associated with in vivo conditions such as cell 
membranes, insolubility, cytotoxicity, and instability. Recent developments of 
prokaryotic and eukaryotic cell-free expression systems provide the means for the 
synthesis of full-length proteins with high yields and a high percentage of functional 
molecules [8]. The simultaneous development of cell-like compartments holds the 
promise of generating large numbers and amounts of biologically active proteins in a 
cell-free manner. This would also permit a simpler creation of molecules with internal 
modifications, such as the addition of non-natural amino acids or options for 
permutation experiments, which may support developments towards personalized 
medicine [76,77]. 
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1.2.2 Cell-Free Expression Protein Microarrays 
To explore this alternative strategy for protein production, several methods have 
attempted to fabricate cell-free protein micromicroarrays. Proteins were produced using 
the in vitro transcription and translation system directly from a DNA template, either as 
plasmid or linear DNA, encoding for full-length proteins or protein domains. Towards 
these means we had previously developed a cell-free expression strategy to generate 
protein microarrays called multiple spotting technique (MIST) where unpurified PCR 
products are spotted as DNA templates, followed by placing the cell-free expression 
system directly on top of the spotted DNA (Fig. 2a) [11]. As little as 35 fg DNA 
template can produce detectable expressed proteins. Since the templates are prepared by 
PCR, they can be modified by adding epitope tag sequences or by changing the base 
sequence of the templates. Protein microarrays containing several hundred human 
proteins have been produced by this method. Here we describe a novel strategy of an 
immobilized DNA template for in situ protein microarrays (Fig. 2b). The attached DNA 
can be directly synthesized on the slide surface using on-chip PCR technology. 
 
Figure 2. Schematic of MIST and personalized proteins microarrays. (a) MIST – 
spotting of DNA template and transfer of cell-free mixture on top of the every same spot in 
a second spotting run. (b) In situ cell-free expression of a personalized protein microarray. 
A nucleic acid programmable protein array (NAPPA) has been used to generate 
protein microarrays by printing biotinylated plasmid DNA, avidin, and GST antibody 
simultaneously onto glass slides and then translating the target proteins by immersing 
the array with rabbit reticulocyte cell-free system. Epitope tags fused to the expressed 
proteins allowed them to be immobilized in situ. The technology has been applied to 
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map pairwise interactions among 29 human DNA replication initiation proteins, 
recapitulate the regulation of Cdt1 binding to select replication proteins, and to map its 
geminin-binding domain [10,78]. In a different strategy, two slides are used in a 
technology called DNA array to protein array (DAPA). Here, cell-free lysate is placed 
between the two slides, the first slide immobilizing the PCR-generated DNA as protein 
expression templates and the second capturing the expressed proteins [9]. Although, the 
immobilized DNA can be reused to produce several replicates of protein microarrays, 
only small numbers of proteins have been reported so far. 
To achieve high-density in situ cell-free protein expression, the surface must be 
strong enough to immobilize the protein but still maintain its native function and also 
provide minimum disturbance of the background. Nonspecific or specific orientation 
are the two options that have been developed in this regard [11]. Chemically modified 
surfaces with active functions such as aldehyde or epoxy groups bind to –NH2 on the 
protein molecules. Lysine residues provide an unprotonated primary amine that can 
interact with epoxy groups in moderate alkaline pH and form covalent bonds with 
protein molecules by nonspecific orientation [79]. The most general approach for 
specific orientation of immobilized protein is the use of recombinant tags, particularly 
polyhistidine (His tag). The addition of His tag either at the C- or N-termini have 
commonly been used in recombinant protein technology, because it generally does not 
interfere with the structure and function of proteins [80].  
1.2.3 Detection Method and Data Analysis 
Basically, there are two different detection methods used for specific detection of 
protein microarrays in high-throughput: label-dependent and label-free methods [57] 
Fluorescence and radio labeling of binding partner molecules can directly monitor 
protein interactions on the array [74]. The fluorescence labeling strategy has become 
widely used for detecting proteins on the array due to its effectiveness and its 
compatibility with the existing laser scanner technology [5,81]. For antibody 
microarrays, attomolar sensitivities have been reported [82], and even the detection of 
individual binding events is well in reach [83]. Functional protein microarrays use 
immobilized proteins mounted on a solid support for identifying protein–protein 
interactions. For example, fluorescent-labeled peptides have been used in protein 
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microarray printing of the purified Src homology 2 (SH2) domain and phosphotyrosine 
binding (PTB) domain encoded in the human genome to measure the according 
equilibrium dissociation constants; the peptides act as binding sites for tyrosine 
phosphorylation on the epidermal growth factor receptors [81]. 
Alternatively, label-free methods using biosensors, mass spectrometry, and 
atomic force microscopy technology have been applied on the array format [84].  
For example, a label-free detection method has been developed to improve the 
sensitivity of protein microarrays in examining the interacting molecules by using high-
density GMR (giant magnetoresistance) sensor arrays to quantify the kinetics of 
antibody–antigen binding at zeptomolar sensitivities [85]. Other techniques have been 
applied for protein microarray detection, one of them being surface plasmon resonance 
(SPR) [86]. The split-protein system is another alternative for detecting PPIs, and one 
study has successfully applied a cell-free split-protein system [87]. 
In case of cell-free protein microarrays, much technical variability during 
multistep production affected the array quality [88]. Learning from DNA microarrays, 
there are various methods that can be used to analyze protein microarrays either for one 
or dual channel data intensity. However, one must take into account that data analysis 
for protein microarrays are still not optimized in regard to than previous established 
microarrays. Protein microarray data analysis can be adapted to take advantage of 
several strategies from DNA microarrays, such as spot finding, Z-score calculation, and 
concentration-dependent analysis [89]. The normalization strategies that have been 
traditionally used in DNA microarrays, such as global normalization, quantile 
normalization, and robust linear model normalization, can reduce variation across the 
arrays [88]. A new approach for background correction called ProCAT is useful to 
correct background bias and spatial artifacts [90]. 
1.3 On-Chip PCR Technology 
DNA microarrays are able to rapidly perform gene expression analyses; they are used 
for profiling in functional genomics, drug discovery, and diagnostics, for mutation 
analyses, and in various applications in microbiological and molecular medicine. DNA 
chips are produced by different means: usually immobilized oligonucleotides are 
spotted directly by a photolithographic process onto glass, silicone, or plastic as solid 
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support [91]. Primer extension of immobilized oligonucleotides at the 5′ end by DNA 
polymerase was introduced in the early 1990s [92]. DNA synthesis on the chip 
principally uses solid-phase amplification by means of DNA polymerase. On-chip PCR 
has been introduced to synthesize DNA based on the extension of one or two primers 
that are covalently attached to the surface by DNA polymerase. The immobilization of 
single- or double-stranded oligonucleotides at the 5′ end allows the free 3′ end to serve 
as a primer. The technology has also been referred to as solid-phase PCR [12] or bridge 
amplification [93]. Different strategies of primer attachment have been employed to 
obtain high amounts of amplified products immobilized on the solid support [12]. 
1.3.1 Solid-Phase PCR 
One part of the basic concept of on-chip PCR is to amplify a given DNA template to the 
attached 5′-end primers through a polymerase reaction, that was introduced as 
solid-phase DNA amplification or solid-phase PCR [92]. Solid-phase PCR can make 
use of one immobilized primer with another one free in the solution [12] or two 
immobilized primers on a solid surface [93]. In this work, a pair of oligonucleotides 
was used as forward and reverse primers. The primers were covalently attached at the 5′ 
end to allow polymerase to copy the DNA template onto the immobilized 
oligonucleotides [12]. Figure 3 illustrates the process of solid-phase PCR to generate 
covalently bound PCR products and the detection methods of DNA products.  
The solid-phase PCR is similar in each step to standard PCR, except that primers 
are bound to the surface. The reactions are begun with denaturation of a freely diffusing 
DNA template into single strands. Then, a complementary region of the single-strand 
template anneals to the attached primers and DNA polymerase extends the 
oligonucleotides. The steps are repeated in an iterative way. Elongation products from 
solid-phase PCR (max. 6 kb long) have been used to detect single nucleotide 
polymorphisms (SNPs) in human mitochondrial DNA (mtDNA) [94] and it was shown 
that the entire human mtDNA genome can be synthesized on a chip [95]. This 
technology platform also has been used to detect and identify bacterial strains [96] and 
to perform on-chip reverse transcription PCR [97]. 
INTRODUCTION 
14 
 
 
Figure 3. On-chip PCR. (a) Solid-phase PCR. The immobilized oligonucleotides anneals 
to a freely diffused DNA template; elongation takes place through DNA polymerase 
activity on a solid surface. (b) Probe detection and second run of solution PCR are the 
confirmation strategies of on-chip PCR products. 
1.3.1 Surface Chemistry 
On-chip PCR employs DNA polymerase to extend the free 3′ of a 5′ end immoblized 
primer, copying the given DNA template [92]. Full accessibility must be guaranteed for 
the DNA polymerase and for primer annealing. One or two oligonucleotides are 
attached covalently onto the solid support (microbeads, microtiter plates, or glass 
slides) [95,96,98]. The primer pair is covalently bound at the 5′ end to the slide surface 
and the 3′ end is left available for amplification reactions in the functionalized DNA 
microarray [12]. The covalently bound single or double strands can be detected by 
radioactive, enzymatic, or hybridization methods [95,99,100]. The covalent linkages are 
thermally stable as demonstrated by modifying the oligonucleotides at the 5′ thiol and 
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immobilizing them onto an amino-silanized surface using heterobifunctional crosslinker 
reagents [12]. Phosphorylated oligonucleotides covalently bound to polystyrene 
surfaces coated with carbodiimide groups and APTES silanized surfaces [95,100]. 
In order to perform on-chip PCR through solid-phase amplification technique, the 
immobilized oligonucleotides serving as PCR primers must be covalently linked via 
their 5′ end so as to not become affected by repeating thermal cycles [12]. A direct 
covalent attachment under mild conditions is preferable considering that downstream 
applications involve many enzymatic reactions. The 5′-amino-modified ends of 
oligonucleotides are immobilized onto the epoxy surface directly and used for detecting 
specific mutations via hybridization methods [101]. Additional linkers and spacers 
improve the efficiency of primer elongation by polymerase activity [98]. 
Incubation times of more than 4 h are required for immobilizing the probe 
molecules (like oligonucleotides) under the particular chemical and humidity conditions 
[102]. Betaine may be used in the spotting mixture of PCR products or oligonucleotides 
to reduce evaporation during transferring PCR products to the array surface [103].  
A comparison of gel-coated and chemically modified non-gel-coated glass slides (with 
polylysine and aldehyde) showed that the latter provided certain advantages for protein 
immobilization regarding spot morphology and reproducibility [104]. Aminosilane 
surfaces are prepared by coating organosilane slides with primary amine. Primary 
amino-coated glass slides in aqueous solution < pH 9 carry positive charge and can 
form electrostatic interactions with anionic oligonucleotides or cDNA facilitated by UV 
exposure or high temperatures [105].  
For the purpose of personalized protein microarrays, the slide surface plays a 
crucial role. Firstly, one of the three main considerations for choosing the type of solid 
support is that the surface must support specific covalent interactions of the 
oligonucleotides at the 5′ end. Nonspecific interactions with the PCR cocktail can be 
minimized using effective blocking methods. Finally, the surface must also be able to 
immobilize the newly synthesized protein from in situ cell-free expression. Specific 
orientations of the oligonucleotides serving as primer pairs are important, so the 
immobilization should not modify these structures nor interfere with base pairing or 
DNA polymerase activity. Proteins can be fused by epitope tagging, which can be 
applied for immobilization and for detection purposes. 
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1.3.2  Oligonucleotides and Conjugation Chemistry 
The modification can be placed at the 5′ end, 3′ end, or internally using amino dC- or 
amino-dT-modified base. The purine and pyrimidine bases provide sites for 
nucleophilic and electrophilic displacements. A strong nucleophile, such as hydrazine 
and hydroxylamine, can be placed at the 5,6-double bond of pyrimidine in a 
spontaneous reaction generating a stable modification at the C-5 position. As the 
electrophilic sites are less advantageous for direct coupling, halogenations of the C-5 
cytosine, for instance, with bromine, can be used to couple diamine spacers to the ring 
structure. Electrophilic alkylation reactions are more effective than nucleophilic 
reactions to modify purine [79]. 
The hydroxyl groups are effective for conjugation or modification reactions with 
alkylating agents or epoxide. In the DNA and RNA chain, the 5′ phosphate group can 
be modified using condensation agents such as carbodiimides or phosphoramidite 
derivatives to produce modified nucleotides containing fluorescent, biotin, chelating, or 
spacer groups. Nucleic acids provide many sites for crosslinking and modification 
although only one or two of these positions are suitable for specific covalent 
attachments of oligonucleotides to a solid surface. This internal modification can 
negatively interfere with oligonucleotide hybridization; modification at the 3′ and 5′ 
ends can help to prevent this [79].The efficacy of attaching oligonucleotides onto a 
chemically active surface for the most part depends on how these molecules are 
modified [106]. The functional groups usually linked to oligonucleotides are aldehydes, 
primary amines, phosphates, biotin, and thiols [79]. The modified oligonucleotides are 
attached to the glass surface coated with electrophilic groups (e.g., aldehyde, epoxy, 
isothiocyanate, and activated esters) through direct or indirect immobilization strategies. 
The most commonly employed oligonucleotides are modified by primary amines at the 
5′ or 3′ ends and covalently immobilized onto the aldehyde- or epoxy-coated glass 
surface by direct coupling reactions [107]. The covalent attachment of aminated DNA 
on aldehyde-activated glass has shown better efficiency for hybridization compared to 
aminated, carboxylated, and phosphorylated DNA on carboxylic acid or amine-
modified glass supports [107]. Similar conjugated chemistry of DNA on aldehyde-
modified glass slides stabilized by dehydration allows covalent bond formation via 
Schiff base reaction and has been used to generate DNA microarrays [107]. 
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A high efficiency of hybridization was also shown for 5′-end succinylated 
oligonucleotides covalently attached to amino-derivatized glass slides by carbodiimide-
mediated coupling [108]. Alternatively, 5′-disulfide-conjugated oligonucleotides bound 
covalently to mercaptosilane-modified glass slides have provided a high-density 
substrate for nucleic acid hybridization. External thiol-modified DNA oligomers can 
covalently attach to silane-coated silica slides by using heterobifunctional 
crosslinkers [109]. Thiol modification also has been used to introduce disulfides to 
oligonucleotides and represents an efficient and specific covalent attachment chemistry 
for immobilization of DNA probes onto 3-mercaptopropyl silane-derivatized glass 
slides [67]. 
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2 MATERIALS AND METHODS 
2.1 Materials 
Equipment 
Name  Manufacturer  
Centrifuge 5415D Eppendorf, Germany  
Centrifuge 5810R Eppendorf, Germany  
Heareus Oven  Thermo Scientific, USA 
Hoefer TE 70 (Semi-dry Western-Blot)  Amersham Bioscience, USA  
Mini-Protean
®
3 electrophoresis chamber and 
   casting unit  
BioRad, USA  
NanoDrop ND 1000 Spectrophotometer  Thermo Scientific, USA  
PCR Thermocycler PTC200  MJ Research BioRad, USA  
pH-Meter MP 230 Mettler Toledo Mettler Toledo, Germany  
Photometer (UV/Vis) Ultrospec 2000 Pharmacia Biotech, Germany 
Power Scanner Tecan, Switzerland 
ScanArray 5000  Perkin Elmer, USA  
Labware 
Name  Manufacturer  
96-well culture plate Greiner Bio-One, Germany 
Cell culture microplate,96 and 384 well,  
   F-bottom 
Greiner Bio-One, Germany 
Cell culture Petri dishes 96  20 mm  Corning Life Science, USA 
Clean, covered 4-chamber incubation tray  Greiner Bio-One, Germany 
Disposable cuvettes UV Eppendorf, Germany  
Eppendorf Safe-Lock tubes 1.5 mL and 2 mL Eppendorf, Germany 
Falcon 15 mL and 50 mL  Greiner Bio-One, Germany 
Gene Frame
®
 Thermo Scientific-ABgene
®
, 
Germany  
Latex gloves  Latex, Blossom Mexpo, USA  
Lazy-L-Spreaders  Sigma-Aldrich, USA  
Microtiter cover film  Nunc, Germany 
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NEXTERION® Slide E Schott Technical Glass Solution 
GmbH, Jena, Germany 
Nickel Chelate Slides Xenopore, USA 
Nitril gloves  Nitril, Microflex, Austria  
Parafilm PM 996 Fisher Scientific, USA  
Polypropylene Microplates 96 and 384 well 
  for PCR 
Greiner Bio-One, Germany 
ProPlate 16-well slide module – 7 mm  7 mm  Grace Bio-Labs, USA 
ProPlate 1-well module, 16 mm  70 mm Grace Bio-Labs, USA 
Sterile filter 500 mL  Nalgene, USA  
Whatman
®
 UNIPLATE microplates 
  384 well, V-bottom 
GE Healthcare Life Sciences, 
Germany 
Chemicals 
Name  Manufacturer  
1,2-Bis(dimethylamino)ethane (TEMED)  Roth, Germany  
2-Ethanesulfonic acid (HEPES) Roth, Germany  
Acrylamide/Bisacrylamide  Roth, Germany  
Agar  Roth, Germany  
Agarose  Invitrogen, USA  
Ammoniumpersulfate (APS)  Roth, Germany  
Ampicillin (sodium salt)  Genaxxon, Germany  
BSA (bovine serum albumin)  Sigma-Aldrich, Germany 
Chloramphenicol  Genaxxon, Germany  
Disodium phosphate (Na2HPO4) Roth, Germany 
DL-Dithiothreitol (DTT)  Sigma-Aldrich, Germany 
Ethanol, absolute  Sigma-Aldrich, Germany 
Ethidium bromide  AppliChem, Germany  
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Germany 
GeneRuler 1 kb DNA marker  MBI Fermentas, St. Leon-Rot  
GeneRulerTM 100 bp DNA marker  MBI Fermentas, St. Leon-Rot  
Glycerol  Sigma-Aldrich, Germany 
GoTaq
®
 DNA Polymerase Promega, USA 
Green fluorescent protein (GFP) Millipore, Billirica, MA, USA 
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Imidazole Roth, Germany  
Isopropyl-β-D-thiogalactopyranoside (IPTG) Roth, Germany  
Kanamycin  Genaxxon, Germany  
Methanol  VWR, Germany  
Monosodium phosphate (NaH2PO4) Roth, Germany 
Oligonucleotides Biomers, Germany 
Oligonucleotides Sigma-Aldrich, Germany 
Protein-Marker: Broad Range  NEB, Germany  
QIAGEN's 10 PCR buffer Qiagen, Germany 
Sodium chloride (NaCl) Sigma-Aldrich, Germany  
SuperScript
®
 III Reverse Transcriptase Invitrogen, Germany 
SYBR
®
 555 Nucleic Acid Stain Invitrogen, Germany 
Taq DNA Polymerase Qiagen, Germany 
Tetracyclin  Genaxxon, Germany  
Tris-base  Sigma-Aldrich, Germany 
Tris-HCl  Sigma-Aldrich, Germany 
Triton X 100  Gerbu, Germany  
TRIzol® Reagent Invitrogen, Germany 
Tryptone/Peptone  Roth, Karlsruhe, Germany  
Tween 20  Sigma-Aldrich, Germany 
XL1-Blue MRF′ Supercompetent Cells Stratagene, Agilent, USA 
Yeast extract  Gerbu Biotechnik, Germany  
Kits 
Name  Manufacturer  
Cloned AMV First-Strand cDNA Synthesis Kit Invitrogen, Germany 
Pierce HisPur cobalt spin columns  Thermo Scientific, USA  
ProFoldin DNA Topoisomerase I Assay Kit ProFoldin, USA 
ProFoldin DNA Topoisomerase II (Gyrase) Kit ProFoldin, USA 
QIAGEN LongRange PCR Kit Sigma-Aldrich, Germany 
Qiagen QIAprep Spin Miniprep Kit  Qiagen, Germany  
Qiagen QIAquick PCR Purification Kit  Qiagen, Germany  
S30 T7 High-Yield Protein Expression System Promega, USA 
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Buffers and media 
Name  Composition  
0.5 M EDTA pH 8.0 Dissolve 186.1 g Na2EDTA∙2H2O in 800 mL dH2O. 
adjust pH to 8.0 with NaOH (~20 g of NaOH 
pellets). EDTA will dissolve at pH 8.0.  
Adjust volume to 1 liter with dH2O. Sterilize by 
autoclaving and store at room temperature 
1 M Ethanolamine 60.5 ml ethanolamine in 1000 mL 
1 M NaH2PO4 (monobasic) 138 g NaH2PO4∙H2O in sufficient H2O to make a 
final volume of 1 L 
1 M Tris-HCl pH 6–8 12.1 g Tris base in 100 mL H2O, adjust pH with 
concentrated HCl 
10 M NaOH 40 g NaOH in 100 ml H2O 
1M HEPES-NaOH pH 7.5 Dissolve 238.3 g HEPES in 1 L H2O. Use NaOH 
pellets to adjust pH to 7.5. Start with about  
5.5 g NaOH pellets 
1M Na2HPO4 (dibasic) 142 g of Na2HPO4 in sufficient H2O to make  
final volume 1 L 
6 Gel-loading buffer 25 mg bromophenol blue and 4 g sucrose, make up 
volume to 10 mL with dH2O, store at 4°C 
6 Gel-loading buffer with 
  Ficoll 
25 mg bromophenol blue, 25 mg xylene cyanol FF 
and 1.5 g Ficoll (Type 400;Pharmacia) in 10 mL 
dH2O, store at 4°C 
Binding buffer 5  0.1 M HEPES pH 8.0, 0.25M KCl, 25 mM DTT, 
0.25 mM EDTA, 5 mM MgCl2, 25% v/v glycerol  
Ethidium bromide solution 0.5 μg/mL final concentration 
Glutathione-free acid-reduced  
  FORM*CRYST 
Sigma-Aldrich Chemie GmbH, Germany 
HEN buffer 250 mM HEPES pH 7.7, 1 mM EDTA, 0.1 mM 
neocuproine (2,9-dimethyl-1,10-phenanthroline).  
Store up to 1 year at room temperature wrapped in 
foil to protect from light 
HMFM 10 (1 Liter) 36 mM K2HPO4, 13.2 mM KH2PO4,  
0.4 mM MgSO4, 1.7 mM Na3C6H5O7,  
6.8 mM (NH4)2SO4, 4.4% (v/v) glycerol:  
0.76 g MgSO4  7∙H2O, 4.5 g sodium citrate 2∙H2O, 
9 g (NH4)2SO4, 440 g glycerol, add water to  
800 mL and autoclave. 18 g KH2PO4, 47 g K2HPO4, 
add water to 200 mL and autoclave.  
Mix both solution to make up final solution. 
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Laemmli buffer  30.1 g Tris base, 144.2 g glycine,  
50 mL SDS (20%), add 1 L dH2O  
LB Agar  LB-medium + 1.5% (w/v) agar  
LB Medium (1 Liter)  10 g Tryptone/Pepton, 5 g yeast extract,  
10 g NaCl, pH 7.2  
PBS 10 (1 Liter)  80 g NaCl, 2 g KCl, 26.8 g Na2HPO4, 2.4 g KH2PO4,  
pH 7.4  
PBST 1 (1 Liter) 1 PBS/0.05% Tween-20 
Spotting buffer (buffer E)  20 mM HEPES-KOH, 0.4mM EDTA, 1 mM DTT, 
100 mM NaCl, 25% v/v glycerol, pH 8  
SSC 20 (1 Liter) 3 M NaCl, 0.3 M sodium citrate buffer pH 7.0 
(dissolve 175.3 g NaCl and 88.2 g sodium citrate in 
800 mL dH2O, adjust pH to 7.0 with 10 N NaOH) 
add dH2O to 1000 mL 
TBE 10 (1 Liter)  108 g Tris, 55 g boric acid, 40 mL 0.5M Na2EDTA, 
pH 8  
TBS 10 (1 Liter)  50 mM Tris, 150 mM NaCl with HCl, pH 7.5  
TBST  1 TBS/0.05% Tween-20  
Transfer buffer  150 mM glycine, 25 mM Tris base, 20% ethanol  
Software 
Name Source 
Bioconductor  Fred Hutchinson Cancer Research Center 
ExPAsy http://www.expasy.org/proteomics 
GenePix Pro 6.0  Axon Instruments, Inc., Union City, USA  
Primer-BLAST http://www.ncbi.nlm.nih.gov/tools/primer-blast 
PROTEIN CALCULATOR v3.3  http://www.scripps.edu/~cdputnam/protcalc.html  
Protein molecular weight  http://www.bioinformatics.org/sms/prot_mw.html 
Random DNA sequence generator http://mkwak.org/oligorand 
Recombinant protein solubility 
  prediction 
http://www.biotech.ou.edu/ 
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Antibodies 
Name  Manufacturer  
AffiniPure Goat Anti-Human IgG,  
  Cy3-conjugate antibody 
Jackson ImmunoResearch, USA 
Anti 6His™ Alexa Fluor® 647 
   conjugates antibody 
Qiagen, Germany 
Anti-CLDN18, antibody Sigma-Aldrich, Saint Louis, MO, USA 
Anti-FLIP, N-Terminal antibody Sigma-Aldrich, Saint Louis, MO, USA 
Anti-FLIPα, C-Terminal antibody Sigma-Aldrich, Saint Louis, MO, USA 
c-Jun (1-169)-GST, soluble Millipore, Temecula, CA 
FOS (Human) recombinant protein (P01) Abnova, Taipei, Taiwan 
Goat Anti-Mouse IgG,  
  Cy5 conjugate antibody 
Jackson ImmunoResearch, USA 
Goat Anti-Rabbit IgG,  
  Cy3 conjugate antibody 
Jackson ImmunoResearch, USA 
Monoclonal Anti CDK2 Sigma-Aldrich, Saint Louis, MO, USA 
Monoclonal Anti-BCL2L1 antibody Sigma-Aldrich, Saint Louis, MO, USA 
Monoclonal Anti-CFLAR antibody Sigma-Aldrich, Saint Louis, MO, USA 
Monoclonal Anti-TP53 antibody Sigma-Aldrich, Saint Louis, MO, USA 
Monoclonal Anti-V5, CY3 conjugate 
   antibody 
Sigma-Aldrich, Saint Louis, MO, USA 
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2.2 Methods 
2.2.1 Constructed DNA Template for On-Chip PCR 
DNA templates for on-chip PCR were constructed by standard PCR reaction.  
Full-length cDNA was constructed for transcription and translation by amplifying 
cDNA clones or first-strand cDNA products. The cDNA products were synthesized 
from isolated RNA from cell lines using TRIzol
®
 Reagent. Basic forward and basic 
reverse primers were used for DNA template construction. Basic forward primers were 
designed with a ribosomal binding site (RBS), Kozak sequence, transcription promoter 
(T7 promoter), 6His epitope tag sequence, and DNA-specific complementary 
sequences. Basic reverse primers contained V5 epitope sequence, stop codon, as well as 
complementary sequence. The constructed DNA templates were purified using 
QIAquick PCR Purification Kit in the standard protocol provided by the manufacturer. 
Afterwards, DNA template concentration was quantified using NanoDrop ND 1000 
Spectrophotometer. The unique gene-specific primer sequences are listed in  
the Appendix (List of primers). 
Basic primers 5′  3′ 
Forward_basic TCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTAGCCACCATGGTAA
GAAGGAGATATACCATGCATCATCATCATCATATGxxxxxxxxxxxxxx 
Reverse_basic CTGGAATTCGCCCTTTTATTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCyyyyyyyyyyyyyyyyyy 
Highlighted colors: yellow T7 promoter; green Kozak sequence; blue RBS.  
Underlined sequences encode epitope tags 6His (red) and V5 (green). 
 
Solid-phase PCR primers were designed consisting of four main parts, from 
5′ to 3′: 1) C6 amino linker, 2) 10T sequence as a spacer, 3) common sequences (blue), 
and 4) complementary sequences, respectively. Complementary sequences were  
17–20 bp of downstream basic forward and reverse primers. A short primer pair was 
also synthesized for solution amplification. All the oligonucleotides were desalted and 
purified by HPLC. 
Solid primers 5′  3′ 
Fow_comOCP (NH2-C6T)TTTTTTTTTTTTTCAGCAGTGTACAGATGGTGATGATGTCCCGCGAAATTAATACGACTC 
Rev_comOCP (NH2-C6T)TTTTTTTTTTTTGCCACTTACCCCACAACCAGACGTTATTACGTAGAATCGAGACCGAGG 
 
Short primers 5′  3′ 
Fow_Sol_OCP TCCCGCGAAATTAATACGACTC 
Rev_Sol_OCP TTATTACGTAGAATCGAGACCGAGG 
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2.2.2 Primer Spotting, Slide Blocking, and Washing 
Epoxy slides (NEXTERION

 Slide E, standard dimensions of 75.6 mm  25.0 mm  1.0 mm) 
were chosen for this experiment as a solid support for covalent attachment of 5′-end 
amino-modified primers. Primers in spotting buffer were spotted using a NanoPlotter 
2.0 (Gesim) noncontact spotting system. Primers were spotted in a concentration range 
from 0.1 to 20 µM and volumes of 0.3 (V1), 0.9 (V2), and 1.5 nL (V3). Primers were 
diluted in spotting buffer A: 150 mM phosphate buffer + 0.001% Tween-20, buffer B: 
3 SSC, and buffer C: 3 SSC + 1.5 betaine. Printed slides were immobilized at room 
temperature at 70% humidity for 3 h, 24 h, and 72 h. Afterwards, slides can be stored 
within 8 weeks under inert condition in a desicator and protected from light at room 
temperature before applying to on-chip PCR. Prior to on-chip PCR, unreactive epoxy 
groups were deactivated using 150 mM ethanolamine, 100 mM Tris-HCl pH 9 for 1 h at 
55C. Alternatively, slides were blocked using 2% BSA in 1 PBST for 30 min at 30C 
and then slides were rinsed in water and dried by pressurized air.  
2.2.3 Solid-Phase PCR 
Surface bound DNA for protein expression templates were generated by amplifying the 
gene of interest from the constructed DNA template. The solid-phase PCR cocktail mix 
contains all PCR components, but minus the primers. The adhesive gene frame (Thermo 
Scientific 11 cm) was fastened around the spotted primer, 25 µL of the PCR cocktail 
were placed inside the frame, and sealed with coverslip. The PCR cocktail contained, 
1 LongRange Qiagen PCR buffer, 2.5 mM MgCl2, 0.5 mM each dNTP, 5–30 ng/µL 
DNA template, and 1 unit of LongRange PCR enzyme mix per 25 µL reaction. The 
slides were then placed into a 1616 dual-block thermocycler (PTC 200, MJ Research). 
Reactions were performed under the following conditions: 93C for 3–5 min and 35 
cycles (93C for 45 sec, 50C for 45 sec, and 68C for 3–5 min) and 68C for 10 min. 
2.2.4 Probe Hybridization 
After PCR, slides were rinsed with water to remove the PCR cocktail and pressured-air 
dried. A probe pair was always used to detect either immobilized primers or DNA from 
solid-phase PCR products. Fluorescently labeled (Cy3 and Cy5) probes were prepared 
with each concentration 1 µM in 3 SSC, 0.1% SDS, and hybridized onto glass slides 
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using lifter slip with following protocols: 95C for 10 min and transfer immediately into 
water bath at 60C for overnight. Slides were washed in 3 SSC, 0.1% SDS for 10 min 
continued with 3 SSC and 0.3 SSC for 10 min each. Slides were rinsed with water 
and pressured-air dried. The signal intensity of the labeled probe was detected using 
laser scanner. 
2.2.5 Solution-Phase PCR 
Slides from solid-phase amplification were rinsed in water for 5 min and dried. New 
adhesive gene frames were placed and filled in with PCR cocktail containing all 
components except the DNA template. PCR cocktail contained, 1 Qiagen PCR buffer, 
2.5 mM MgCl2, 0.2 mM of each dNTP, 0.2 µM of each short primer, and 1 unit of Taq 
polymerase. Slides were sealed with a flexible and removable coverslip and placed in 
the thermocycler. The PCR protocol followed that applied in solid-phase amplification. 
The PCR products were collected and resolved on 1–1.5% agarose gel by 
electrophoresis. 
2.2.6 In Situ Cell-Free Expression of On-Chip PCR Products 
For protein expression, slides from solid-phase PCR were washed using 1 SSC twice 
for 5 min each and dried. The multiple spotting technique (MIST) was applied for in 
situ cell-free expression [11]. Slides were arranged at the same position where primers 
were spotted. Firstly, 0.6 nL of 0.5 M betaine were spotted on top of bound PCR 
products and followed by 2.1 nL of S30 T7 High-Yield Protein Expression System 
(Promega). Slides were incubated for 1 h at 37C and at 28C overnight in humidified 
chamber. After incubation, slides were stored at –20C for a minimum of 24 h before 
protein detection. 
2.2.7 High-Throughput Culture of cDNA Library 
3500 DNA samples of full-length human open reading frames (ORFs) human cDNA 
clones were obtained from The Gateway Full ORF Clones (German Cancer Research 
Center, Genomics & Proteomics Core Facilities (Appendix, List of genes). Escherichia 
coli with individual inserts of full-length human open reading frames (ORF) of 
individual cDNA libraries were subcultured as working libraries. Cells were inoculated 
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in LB medium containing 30 µg/mL kanamycin as selective antibiotic and 1 HMHM 
as cryoprotectant. Individual wells of 120 µL volumes in 96-well cell culture 
polystyrene microplates were inoculated with 1 µL of bacterial culture and grown at 
37C overnight. Bacterial cultures were stored at –80C. 
2.2.8 High-Throughput Colony PCR for High-Density Protein Microarray 
An amount of 15 µL of overnight bacterial colony were diluted into 50 µL using sterile 
water, and heated at 85C for 15 min. Five µL of the heat-killed bacteria was used as 
template for gene-specific amplification and the rest stored at −20°C for future use. The 
master mix for PCR reactions was prepared into the following final concentrations:  
1 Qiagen PCR buffer, 100 µM of each dNTPs, 0.1 µM of each primer, 5 µL of 
pretreated bacterial colonies, and 2 units of DNA polymerase for every 25 µL reaction. 
Basic forward primers and basic reverse primers were used to construct complete full-
length cDNA for in vitro transcription and translation. Thermal cycles were performed 
at 95C for 5 min, continued with 95C for 45 sec, 50C for 45 sec, and 72C for 3 min 
and repeated 35 times. Finally, the cycles were completed at 72C for 10 min. The PCR 
products were validated by 1−1.5% agarose gel electrophoresis. 
2.2.9 Small-Scale Standard PCR  
The ORF of interest were isolated from the overnight culture in 2 mL LB medium 
containing 30 µg/µL kanamycin. These complete coding sequences lack stop codons. 
Plasmids carrying inserts of ORF were isolated from overnight cultures using QIAprep 
plasmid DNA purification (Qiagen, Germany) following the manufacturer protocol. 
The concentration of the isolated plasmid was determined using NanoDrop 1000 
Spectrophotometer. Each isolated plasmid was aliquoted into working concentrations of 
50 ng/µL and stored at –20°C. The master mix for PCR reactions was prepared into the 
following final concentrations: 1 Qiagen PCR buffer, 100 µM of each dNTP, 0.1 µM 
of each primer, 5 ng/µL DNA, and 2 units of Taq polymerase for every 25 µL reaction 
sample. Basic forward primers and basic reverse primers were used to construct 
complete full-length cDNA for in vitro transcription and translation. Thermal cycles as 
previously described above. The PCR products were validated by 1−1.5% agarose gel 
electrophoresis. 
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2.2.10 High-Density Protein Microarrays by MIST 
The PCR products for protein microarray production were diluted 1:2 in nuclease-free 
water containing 0.5 M betaine, then transferred into 384-well spotting plates, followed 
by quick spindown in a centrifuge. The cell-free transcription and translation mixture 
was prepared as recommended by the manufacturer (S30 T7 High-Yield Protein 
Expression System, Promega). Ni-NTA- and epoxysilane-coated slides were used. The 
spotting area is defined for an area of 72 x 22 mm. PCR products were first spotted onto 
the slide surface; then the cell-free lysate was spotted on top of the PCR products in a 
second spotting run [11]. Slides were incubated for 1 h at 37C and then at 28C 
overnight in humidified chamber. After incubation, slides were stored at –20C for a 
minimum of 24 h before protein detection. 
2.2.11 Antibody Detection of Expressed Protein 
The newly expressed proteins can be detected using antibodies that recognize  
N- and C-terminal tags as well as with protein-specific antibodies. Prior to antibody 
interactions, the slides were blocked using 2% BSA in 1 PBST for 30 min on orbital 
shaking at 30 rpm at room temperature. The fluorescent conjugated epitope tag antibody 
was diluted to 0.1 µg/mL in the blocking buffer, and for protein-specific antibodies to 
0.5 µg/mL. This was incubated for 1 h in a rotary shaker at 30 rpm at room temperature. 
In the case of the epitope tag antibody, the antibody solution was removed and slides 
were washed; after 1 h of incubation, the antibody solution was replaced with a 
1:10,000 dilution of fluorescent conjugated secondary antibody. Incubation was 
continued for another hour. After incubation, slides were washed three times with  
1 PBST for 10 min each, rinsed with PBS, and dried. The expressed proteins were 
detected by laser scanner. 
2.2.12 Data Acquisition and Analysis 
Slides were scanned on a ScanArray 5000 or NimbleGen MS 200 Microarray Scanner. 
The instrument laser power (LP) and the photomultiplier tube (PMT) were adjusted to 
obtain visible signals for most spots, with only a small number of saturated signals. 
These scanner settings were maintained for all arrays in one experimental series. 
The recorded scanned image was converted into signal intensities by the spot 
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recognition software GenePix Pro. The false-color images were also generated with 
GenePix Pro. For on-chip PCR data analysis, the mean local background intensity was 
subtracted from the mean signal intensity for each spot to obtain background-corrected 
signal intensities. The background-corrected intensities for the red and green channels 
are designated R and G. The log converted intensities of the spots were calculated by  
A = (log2 R + log2 G)/2, a measure of the overall brightness of the spot [110]. The A 
value of each spot represents the amount of detected primer pairs and on-chip PCR 
products on the microarray. 
The high-density protein microarrays were analyzed primarily using the software 
package LIMMA (Linear Models for Microarray Data) within an R-Bioconductor 
package [111,112]. Data loading via LIMMA for each spot consisted of the arithmetic 
mean value intensities of the pixels, R for N-terminal (red) and G for C-terminal 
detection (green), and the mean of the pixel values of the local background (Rb, Gb). In 
addition, quality information was added where available. The quality of one array from 
each batch of protein microarrays was verified using: 
 Plot of C-terminus signal intensities of expressed proteins derived from purified 
and unpurified PCR products. 
 Plot log2 N- and C-terminus signal intensities of expressed proteins on Ni-NTA and 
epoxy slides. 
 Box plots of log2 signal intensities were made to examine the uniformity of signal 
intensities, signal intensity ratios, and coefficients of variation (CV) within (intra-) 
and across (inter-) arrays of each batch production. 
 Density plots of log2 signaly intensities were examined to check whether the 
intensities from two-color detections evenly distribute. 
 Scatter plots log2 C-terminus signal intensities and protein sizes were examined to 
obtain the distribution of expressed proteins based on their sizes. 
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3 RESULTS 
3.1 On-Chip PCR and Personalized Protein Microarrays 
To exploit the basic principle of solid-phase PCR for the production of DNA templates 
for cell-free on-chip expression, we optimized the solid-phase PCR method and 
generated arrays containing a DNA template encoding a full-length human protein 
fused with an N-terminal 6His and C-terminal V5 tag, together with the required 
sequences. 
3.1.1 Evaluation of Spotting Buffer and Primer Concentration 
We optimized several parameters that are susceptible to affect covalent attachment of 
5′-amino-modified oligonucleotides onto epoxy slides including primer concentration, 
spotting buffer, blocking, and washing conditions. The epoxy slide was selected 
because it has previously been reported to give stable covalent attachments of 5′-amino-
modified oligonucleotides [101,102]. The attachment of covalently bound oligo-
nucleotides was also relatively thermostable [12]. The spotting buffers described in the 
literature were selected because they readily allow covalent interactions between amino 
groups and opening epoxy groups [112]. The forward and reverse primers were diluted 
in three different spotting buffers and spotted using noncontact spotter in a 
concentration range from 0.1–20 µM and volumes of 0.3 (V1), 0.9 (V2), and 1.5 nL 
(V3) – spotting buffer A: 150 mM phosphate buffer +0.001% Tween-20, buffer B:  
3 SSC, and buffer C: 3 SSC + 1.5 betaine. The 60mer primer contained 5′-C6 amino 
linker and 10Ts spacer to improve probe hybridization efficiency as well as primer 
extension during solid-phase amplification [98,107]. 
The spotted primers were detected after 24-hour immobilization in 60–70% 
humidity by hybridization using fluorescent complementary probe. Prior to probe 
hybridization, slides were blocked and washed to deactivate unreacted epoxy groups 
and remove unbound primers. Spotting buffer A and B showed perfect spot 
morphology, but spotting buffer C produced a doughnut-like spot shapes at 
concentrations lower than 5 µM (Fig. 4a). 
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Figure 4. Dependence of detected solid-phase PCR products on spotting buffer and 
primer concentration. (a) False-color images from probe detection of elongation of 
forward primers (red spots), reverse primers (green spots), and overlay image from both 
strands (yellow spots). (b) Overall signal intensity of spotted primer in three different 
spotting buffers. Spotting buffer A: 150 mM phosphate buffer pH 8.5 +0.001% Tween-20, 
buffer B: 3 SSC, and buffer C: 3 SSC+1.5 betaine. Plots of average log red and green 
signal intensities (A value) for buffers A (i), B (ii), and C (iii) in three different spotting 
volumes are represented by blue (V1), red (V2), and green (V3) lines, respectively. 
The regular shape of spots indicated that the chemical composition in these 
spotting buffers facilitates an homogeneous distribution of primer molecules in the spot. 
The spot size depends on spotting volume and concentration, particularly for spotting 
buffer A. Betaine solution in buffer SSC (buffer C) did not significantly affected the 
spot morphology of spotted primers on epoxy slides. However, it has been reported that 
combination of SSC and betaine can improve DNA immobilization efficieny on poly-L-
lysine slides by preventing evaporation [103]. 
a 
b 
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Spotting buffer A gave bigger spot diameters than the other two buffers. The 
presence of nonionic detergent in spotting buffer A increased the distribution of primer 
molecules in the spot. The signal intensities of detected primers spotted by means of 
buffer A were higher than for the other two buffers reaching saturated spotted primer 
concentrations at 5 µM, but not with the other buffers (Fig. 4b). Optimal concentrations 
must be determined for each type of molecule, because the spotting concentration is 
inversely dependent on the molar mass of molecules [102]. The chosen blocking 
method was suitable to reduce the background of the array. Any unreacted epoxy group 
has to be chemically deactivated to prevent nonspecific binding of the probe to the slide 
surface. A good spotting buffer should give spots of equal size, and with a nice round 
morphology, no change over time, and be resistant to evaporation during long print 
runs. The overall result from this work suggests the most suitable spotting buffer for  
5′-amino-modified primers onto epoxy slides as being phosphate buffer pH 8.5, 
supplemented with 0.001% Tween-20 and at an optimum concentration of 5 µM. 
3.1.1 Dependence of On-Chip PCR Products on Primer Immobilization Time 
We have optimized the immobilization strategy to obtain thermostable covalent 
attachment of the 5′-end amino-modified oligonucleotides onto epoxy slides. 
Immobilization of molecules through specific chemical reactions requires sufficient 
time to complete the coupling chemistry [102]. The time to immobilize the primers was 
optimized. We also tested the optimum concentration of immobilized primer for 
optimum yield of solid-phase PCR product. Three different immobilization periods 
were chosen and primers were spotted onto the slide surface. The primer pairs were 
diluted in a concentration range from 0 to 20 µM using 150 mM phosphate buffer  
pH 8.5 + 0.001% Tween-20. Then, primers were spotted and incubated in humidity 
chamber (60–70%) for 3 h, 24 h, and 72 h. Afterwards the slides were blocked and 
washed. Three independent probe detections were carried out: first, by complementary 
fluorescence probes before on-chip PCR; then, the immobilized primers were checked 
after the PCR cycles; and finally, checked with DNA-specific probes. For every solid-
phase PCR reaction we always used DNA target at concentration 1 ng/µL. Figure 5 
shows the scanned image and the plot of concentrations of the spotted primers versus 
log intensities from three different immobilization times. 
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The amount of attached primers and DNA products were represented as the log of 
fluorescence signal intensity (A) of both red- and green-labeled probes. Comparing line 
graphs for 3-h, 24-h, and 72-h immobilization, the amount of detected primers before 
being subjected to a thermocycling protocol increased with longer incubation times 
(blue line). This showed that inadequate time for coupling reactions reduced the amount 
of bound primers on the surface. The signal intensities from detected primers after 
thermal cycles (red line) displayed that unbound primers were washed away during  
on-chip PCR, particularly for very short immobilization times (Fig. 5a). Post-
hybridization washing processes also contributed to detaching unstable molecules from 
the surface. This was a major reason for the low yield of detected PCR products 
(Fig. 5a, green line). Although, there was a moderate decrease of detected bound DNA 
(Fig. 5b), one full-day immobilization under humid conditions gave relatively stable 
attachment of 5′-end amino-modified oligonucleotides onto epoxy slides. 
 
Figure 5. Dependence of on-chip PCR products on primer immobilization time.  
False-color image of fluorescent probe hybridization and graph of the spotted primers 
immobilized for 3 h (a), 24 h (b), and 72 h (c). Graph lines are the concentration of spotted 
primers plotted against the log of overall intensities, A. Three independent probe 
hybridizations of the immobilized primers were carried out by complementary fluorescence 
probes before on-chip PCR (blue line/♦) and after the PCR cycles (red line/ ■); then 
detections of the PCR products with DNA-specific probes (green line/▲). Positional 
controls are indicated by red and green arrows (Cy5- and Cy3 oligonucleotides).  
The log signal intensity for detected DNA after PCR cycles in Fig. 5c showed that 
the amount of detected PCR products was higher for primers that were immobilized for 
72 h than only for 3 h or 24 h. There were plateau lines for all three probe 
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hybridizations. With the exception of the lowest primer concentration, all spotted 
primers yielded saturated signals for all primer concentrations. However, the result from 
24-h immobilization indicated that 5 µM was the optimum primer concentration that 
yielded optimum detected PCR product. This result also suggested that higher densities 
of immobilized primers will not increase the yield of DNA amplification on the solid 
surface.  
For on-chip PCR purposes, a minimum of 24 h of incubation in humidity chamber 
was necessary for primer immobilization followed by dry storage for 24 h in order to 
achieve stable covalent attachments and reduce the loss of molecules during washing, 
blocking, and thermal cycles. Carefully adjusted immobilization conditions
 
prevented 
the detachment of primers from the surface during thermal cycling. 
3.1.2 Full-Length DNA by On-Chip PCR 
We have generated arrays containing a DNA template encoding a full-length human 
protein fused with an N-terminal 6His and C-terminal V5 tag, together with the 
required sequences. The immobilized primers can reach extension lengths above 5 kb 
and with an according polymerase system the entire genome of human mitochondrial 
DNA can be amplified, comparing well with the product length produced with standard 
PCR [13,113]. In this work, we generated different sizes of full-length DNA by on-chip 
PCR with a primer pair bound to the surface. The DNA-specific solid-phase primers 
were spotted based on optimum conditions that had been previously described. The 
primers were arrayed onto 30 spots for each PCR grid system. For DNA templates, 
human full-length ORFs were used. Four different lengths of DNA targets were 
selected as proof of principle for the efficiency of DNA polymerase activity in the 
solid-phase PCR. 
The newly synthesized DNA on the surface was detected with DNA-specific 
probes using the hybridization protocol described in the Methods sections (Fig. 6a). 
Subsequently, this DNA was amplified using solution-phase primers and the PCR 
products were detected by 1–1.5% agarose gel electrophoresis (data not shown). Epoxy 
slides were used to obtain thermostable covalent attachments of 5′-end amino-modified 
primers and to ensure the free 3′ end is vacant for DNA polymerase activity. The 10Ts 
linker is added to primer sequences to improve hybridization efficiency [107,114]. 
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Also, for the second run of PCR cycles, we added 20mer nucleotides referred to as 
common sequences. These oligonucleotides were noncomplementary to any given DNA 
template. As little as 7.5 fmole of primer pairs was sufficient to obtain an adequate 
density of immobilized oligonucleotide molecules for effective DNA polymerase 
activity. 
We were able to extend the attached primers into full-length DNA up to 3 kb. The 
amplified DNA products bound to the slide surface were examined by means of Cy-5 
and Cy3-labeled 25–30mer probe complements to the plus and minus strands of the 
corresponding DNA, then visualized by laser scanner. Alternatively, another PCR step 
was implemented to amplify on-chip DNA product using a pair of 18–20mer primers. 
Then, the newly synthesized DNA was generated as PCR products in solution phase 
(data not shown). Mean deviations from the mean signal intensity of detected solid-
phase PCR products for upper and lower strands ranged between 10–20% (Fig. 6b). 
The amount of detected PCR products was independent of the length of amplified 
DNA. 
 
Figure 6. Covalently bound DNA detected by a fluorescent-labeled complementary 
probe. (a) Overlay red and green channels from both DNA strands are shown in the left 
vertical panel, and individual probe detection of single-strand DNA in the center and right 
panel. Four human full-length ORFs were used as DNA templates, DNA 1-4: DIABLO 
(717 bp), IDH3B (1155 bp), CHMP2A (666 bp), and CREB3L1 (1557 bp). Positional 
controls are indicated by red (Cy5-oligonucleotides) and green (Cy3-oligonucleotides) 
arrows. Negatives were spots of spotting buffer only. (b) Bar chart showing the mean of 
the log red and green intensities; CV was calculated for 30 spots in one array. 
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Newly synthesized DNA was detected by DNA-specific probes that recognize 
both strands of DNA. Each probe pair hybridized at a position of approx. two-thirds 
along the DNA. An alternative detection method on second-run PCR used short 
primers. These primers basically have the same DNA complementary sequences that 
were previously used for solid-phase PCR. Since, the second polymerase reaction was 
completed without using new DNA targets, this ensured that the PCR products came 
from the amplification of bound DNA. By using two detection strategies, the full-length 
DNA can be confirmed. This result indicates solid-phase PCR can copy full-length 
DNA into bound primers. The solid-phase PCR method generates covalently bound 
DNA arrays in specific orientation. 
3.1.3 Multiplex Reaction Using On-Chip PCR 
As proof of principle, on-chip PCR was used to amplify double-stranded DNA in a 
multiplex reaction. Highly specific primer pairs were designed with similar melting 
temperatures. These primers were tested for their specificity using the Primer-BLAST 
program [115]. Multiplex solid-phase PCR has been used for a rapid detection of 
bacteria from clinical samples based on the recognition of the 23S ribosomal DNA 
sequences [116]. For this work, five pairs of solid-phase primers were immobilized 
together in one on-chip PCR system. We immobilized five primer pairs in several 
replicates. Figure 7a shows our spotting layout with five primer pairs on the array 
outlining results of primer-pair verification using standard PCR. In parallel, these 
primers were also tested by normal PCR (Fig. 7b, right panel). Then, solid-phase PCR 
was performed; only one DNA target was added for each PCR mixture. The DNA 
targets (DNA1–DNA5) were 300–500 bp fragments of ILR1RN, AK1, CHMP2A, 
IDH3B, and CREB3L1, respectively. After polymerase reaction, slides were detected 
with DNA-specific probes for the validation of primer specificity in multiplex solid-
phase PCR (Fig. 7b, left panel). 
As can be seen in the scanned image for DNA 2 and DNA 3, the solid-phase PCR 
reaction only amplified its own specific DNA target. Primers 2 and 3 specifically 
elongated the given PCR template. This result was consistent with the DNA products 
generated using standard PCR (Fig. 7a, b; right panel). 
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Figure 7. Multiplex solid-phase PCR. (a) Spotting layout of solid-phase primers (left 
panel) and results of primer verification using standard PCR (right panel). (b) False-color 
images of DNA-specific probes (left panel) and gel images of tested primers (right panel). 
For all given DNA in the PCR mixture, the electrophoresis gel for primers 2 and 3 
only showed one band for its own DNA target (Fig. 7b, right panel). Though the 
specificity of the tested primers have been validated in silico, still it showed a cross-
a 
b 
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reaction to nontarget DNA during PCR reaction. Three of the five primer pairs showed 
unspecific results either in solid-phase PCR or standard PCR. The solid-phase PCR 
system can amplify multitargets simultaneously which requires the use of highly 
specific primers to their DNA target. 
In this work, we showed that highly specific primers amplify only their own DNA 
target without significant cross-reactions to other DNA templates. However, less 
stringent primers may exert cross-amplification to nontarget DNA. 
3.1.4 In Situ Protein Synthesis from Covalently Bound of cDNA 
We have utilized a novel strategy of immobilizing DNA templates for in vitro 
transcription and translation directly onto a chip (slide surface). The solid phase of 
specific primers has been tested to produce specific cDNAs from isolated mRNAs by 
using reverse transcription PCR (RT-PCR) [117]. The solid-phase primer pairs were 
used to generate attached full-length DNA on the chip surface, and these served as 
templates for in situ transcription and translation to produce protein microarrays. The 
DNA-encoded proteins were constructed with the necessary sequence for transcription 
and translation as described in the Methods section. Additionally, sequences for 6His 
and V5 epitope were inserted to encode fusion tags at N- and C-termini. Then, the 
construct was used as template in solid-phase PCR to produce covalently bound DNA 
on the surface. The amplified DNA was validated by hybridization of a complementary 
probe. The full length of PCR products was also validated by another PCR step 
detecting the dissolved products by gel electrophoresis. Afterwards, protein expression 
was carried out by spotting these newly synthesized cDNAs with cell-free expression 
lysate and incubating at 37C and at RT (28C) in the humidity chamber for 
transcription and translation. 
The expressed proteins were detected by fluorescent conjugate antibodies that 
recognize fusion epitope tags, as described in the Methods section. Then slides were 
scanned to visualize the expressed proteins (Fig. 8a). In this array, DNA encoding 
CREB3L1, TP53, MAPK1, and DIABLO was synthesized on the slide surface and 
subsequently used for in situ cell-free expression. The expression of bound DNA was 
observed by the fluorescent signal intensity from Cy3- and Cy5-labeled antibodies 
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(red and green spots). The negative controls of solid-phase primers did not emit 
fluorescent signals from any of the antibodies.  
  
 
 
 
 
 
 
 
 
Figure 8. Protein expression from bound DNA templates. (a) False-color images and plot 
signal intensities from epitope detection using fluorescent conjugate antibodies against fusion 
epitope in N- and C-termini of expressed CREB3L1, TP53, MAPK1, and DIABLO. Individual 
scanned images from N- and C-termini are shown by red and green arrays, respectively. The 
inset in each panel shows spots of expressed protein and negative control. Background-
corrected signal intensities of each expressed protein were plotted together with the respective 
negative spots. (b) False-color image of terminal epitope detection of MAPK1 (left panel), 
anti-MAPK1 antibody and fluorophore-conjugated secondary antibody (middle panel), and 
secondary antibody only (right panel). White box indicates spots of negative controls. 
b 
a 
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The arrays were also detected using protein-specific antibodies. MAPK1 was 
expressed in situ from bound cDNA as template. One array was used to verify newly 
synthesized protein with epitope tag antibody. The interaction of anti-MAPK1 antibody 
and protein microarray was shown using fluorescent conjugate secondary antibodies 
(Fig. 8b). The expressed proteins were also incubated with BSA and secondary 
antibody only as negative control. 
The expressed protein on the chip was accessible across both terminus sites.  
C-terminus detection showed that the translation was complete, yielding a full-length 
expressed protein. The protein–antibody interactions showed that the in situ expressed 
proteins obtained directly from covalently bound double-strand cDNA at the 5′ end 
were able to interact with the specific protein antibodies. 
3.1.5 Personalized In Situ Protein Microarrays 
The solid-phase PCR system can be used to perform multiplex reactions (Fig. 7).  
In order to check whether the solid-phase PCR system with multiple primer pairs would 
specifically produce multiple DNA targets, we generated various sequences of DNA 
bound onto the slide surface. To use the optimized construction of the immobilized 
primers that had worked successfully under our solid-phase PCR conditions, we did not 
change the key elements of the immobilized primers, i.e., spacer, linker, and common 
sequences. With an additional unique 5′ end for each DNA template, the immobilized 
primers would specifically recognize their own targets in the PCR mixture. These 
unique oligonucleotide pairs were designed with a very high stringency, but since they 
were added as part of primers, it was easier in setting a uniform melting temperature (Tm). 
Then, with this strategy, multiple primer arrays could be transformed into 
multiple bound DNA templates at a specific orientation. The DNA arrays can be stored 
dry for a reasonable time prior to expressing the proteins. Then, in this particular 
instance we expressed seven coding PCR products as proof of principle to generate 
personalized protein arrays. Using anti-6His and anti-V5 antibodies which recognize 
the fused N- and C-terminal tags, respectively, in each coding sequence, we were able 
to confirm full-length expressed proteins (Fig. 9a). The detected protein signals for all 
tested coding sequences were above the signals from negative control spots (Fig. 9b). 
For testing this concept of personalized protein microarrays we used seven bound DNA 
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templates encoding full-length proteins: DIABLO, CFLAR, TP53, AKT1, MAPK1, 
BCL2L1, CDK2. The success rate of expression varied between these proteins. For 
negative spots yielded signals in the background range. Two of the expressed proteins 
were also confirmed by means of protein-specific antibodies (Fig. 9c, d). The 
antibodies were confirmed for selectivity using high-density protein microarrays 
(Fig. 16). 
Each DNA requires a highly specific melting temperature (Tm) at which a primer 
targets the original sequence of DNA. Additional flanking primer sequences are 
routinely used in next generation sequencing, usually known as adapters [118]. With 
uniform Tm, primer annealing can be easily controlled and nonspecific PCR products 
can be avoided. 
 
Figure 9. False-color images of in situ protein expression. (a) The superimposed images 
are obtained from epitope detection using fluorescent conjugate antibodies against fusion 
epitopes in the N- and C-termini of the expressed proteins. Negative indicates position of 
nontranscribed DNA as negative control. (b) Individual signals from N- and C-termini 
depicted in a bar chart. (c, d) False-color images of CDK2-specific antibodies and BCL2L1 
detection. 
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3.2 High-Density Protein Microarrays  
We have optimized the conditions of MIST for larger-scale production of protein 
microarrays [11]. The array quality was examined to determine and evaluate the 
technical usability and variations induced by PCR, protein expression, and probing. 
Furthermore, protein microarrays produced by the MIST method were tested for 
protein–protein and protein–RNA interactions, as well as for antibody and binder 
selection. 
3.2.1 Purified or Unpurified PCR Products 
Unpurified PCR products were used for our microarray production. The decision was 
supported by the level of expressed proteins from unpurified and purified PCR products 
from the same proteins produced under similar conditions. One volume of PCR product 
(25 µL) was purified using ethanol-based DNA purification methods and eluted with 
25 µL of water. The PCR purification process removed primers, nucleotides, enzymes, 
salts, and other impurities after polymerase reaction [119]. Purified and unpurified PCR 
products were diluted in a similar fashion with spotting buffer. Afterwards, these PCR 
products were spotted to generate protein microarrays. The newly synthesized proteins 
were compared based on signal intensities from Cy3-conjugated V5 antibody 
recognizing the V5 epitope at the C-termini of the proteins (Fig. 10). 
 
Figure 10. Purified and unpurified PCR products used for protein expression on 
microarrays. (a) Protein microarrays of nine proteins and one negative controls, produced 
from purified (i) and unpurified (ii) PCR products. False-color images detect expressed 
proteins using Cy3-conjugated anti-V5 antibody, recognizing V5-fused tags at the  
C-termini. (b) Signal intensities of detected proteins on the array from unpurified (blue) 
and purified (red) expression templates. 
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Table 1. Proteins and purified PCR product concentrations 
Position 1 2 3 4 5 6 7 8 9 10 
Name BCL2A1 VSNL1 BDNF GEM negative ACSBG2 NGEF OGT PHKA2 ICAM3 
Lenght (bp) 525 573 741 888 N/A 1998 2130 3108 3705 3561 
ng/µL 64.0 50.3 51.2 70.6 1.05 70.7 72.6 50.3 95.3 96.7 
 
For all tested genes, unpurified PCR products gave higher detection signal 
intensities, indicating that the amount of expressed protein was higher than if purified. 
Only two out of nine tested proteins gave similar expression levels of unpurified and 
purified samples, which might have been caused by higher spot concentrations 
(Table 1). Interestingly, the negative controls of both purified and unpurified DNA 
showed similar signal intensities. The primers themselves were 120mer and 60mer, 
respectively, that may produce primer dimers of 120–170mer length. The chosen buffer 
in the purification system only removed DNA fragments smaller than 100 bp. This 
indicates that PCR purification will not be able to remove the excess primers and its 
dimers. However, some components usually find in the PCR mixture can inhibit cell-
free expression, such as glycerol at >1% and MgCl2 at >3 mM. As a rule of thumb for 
cell-free expression, higher DNA concentrations will produce higher yields of 
expressed proteins, while not taking protein properties into account. 
3.2.2 Specific or Nonspecific Orientation of Immobilized Proteins 
Two different slide surfaces were used to compare the spot morphology of expressed 
proteins on the array, the amount of detected proteins, and stability of protein 
immobilization. We have expressed 94 human proteins and 12 GFPs on nickel-
nitrilotriacetic acid (Ni-NTA) and epoxy slides. The full-length human proteins and 
GFPs contained N-terminal 6His and C-terminal V5 tag. These two different types of 
coated glass slides immobilized proteins by specific and nonspecific orientation, 
respectively. The addition of His-tag either to the C- or N-termini have commonly been 
used in recombinant protein technology, because they generally do not interfere with 
the structure and function of proteins [80]. The yield of expressed human proteins and 
GFPs were compared for both slides (Fig. 11a). Ni-NTA slides produced smaller spot 
diameters than epoxy slides. Low levels of expressed protein gave doughnut-like 
shaped spots on the epoxy slides. 
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The raw signal detection of expressed GFP was used to compare the background 
signal intensities of the slides (Fig. 11b). After background subtraction, the mean signal 
intensity of detected GFPs on epoxy slides was higher than detected GFPs on Ni-NTA 
slides, as the latter emitted an almost three times higher background signal. All detected 
signal intensities were included in the analysis, both expressed proteins and negative 
controls (Fig. 11c). all experiments were performed in triplicates. 
 
Figure 11. Comparison of protein microarrays on Ni-NTA and epoxy slides. (a) Spot 
morphology of expressed proteins of Ni-TNA slide (upper panel) and epoxy slide (lower 
panel). (b) Comparison of raw signal intensities of detected GFP (blue) and respective 
back-grounds (red). (c) Comparison of background-corrected signal intensities of 90 
proteins expressed on Ni-NTA and epoxy slides. Detection of N-termini (red) and  
C-termini (green) from two slides were compared, as well as negative controls. 
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A comparison of the expression of 94 human proteins on Ni-NTA and 
epoxy-coated  surfaces based on signal intensities from N-termini shows that there is no 
significant difference in the the mean expression on both surfaces (p-value = 0.063). 
Similarly, C-termini detection of V5 epitope tags gave similar results on both slides, 
although there was a slight increase in the number of detected proteins on the epoxy 
surface but no significant difference (p-value = 0.66). This result indicates that both 
specific and nonspecific orientation of protein binding to the surface allows for similar 
interactions with other molecules, in this case antibody. The same result have also been 
reported for direct detection of expressed GFP on APTES and Ni-NTA slide [11]. 
3.2.3 Consistency of Cell-Free Mixture Spotting 
One of the key strategies of MIST is to transfer cell-free expression mix directly on top 
of each DNA spot, and to keep the amount of applied cell-free mix as small as possible. 
To test the variability of spotting process and the consistency of protein expression on 
the array, we expressed 384 GFPs. Intra-array variability was predicted by computing 
the coefficient variation (CV) from the detected signal intensities of expressed GFP. 
Each GFP had three intra- and three interarray replicates. An ANOVA model was used 
to determine the cell-free mixture spotting variation associated with protein expression 
that are resulted from repeated spotting processes. The variance estimate of the random 
errors was used to determine the consistency of cell-free mixture spotting across the 
arrays. 
The expressed GFP was detected using anti-6His antibody recognizing  
C-terminal fusion His-tags. The local background was subtracted from the raw mean 
signal intensity to obtain the background-corrected signal intensity. One single uptake 
by the spotter pin ( volume capacity, 10 µL) was sufficient to transfer cell-free mixture 
to every spot in all three blocks of the arrays (Fig. 12). We found the expressed proteins 
CV to be 12%, 11%, and 13%, for sub-array 1, 2, and 3 respectively. Variation in the 
number and levels of the expressed protein on high-density GFP microarrays using 
MIST was statistically insignificant at the 1% confidence interval (p-value = 0.014). 
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Figure 12. Expression of GFP microarrays. (a) False-color image of one block of GFP 
protein microarrays (left) and plot of mean signal intensity with negative controls. 
(b) Three intrareplicates of the expressed GFP and plot of their signal intensities. 
3.2.4 High-Density Protein Microarrays 
About 3500 full-length human cDNAs were arrayed and expressed in situ using a cell-
free expression system directly on the slide surface (Fig. 13). These proteins were 
arrayed onto two different slides, one slide containing 1656 spots and the other 2070 
spots. Currently, one slide can hold up to 2500 spots. To fabricate protein microarrays, 
a non contact-printing robot was used to deliver nanoliter volumes of PCR products and 
cell-free expression mixture to the slides, yielding spots about 480 to 500 µm in 
diameter (225 spots per square centimeter). The protein microarrays were produced 
from unpurified colony PCR products and expressed using multiple spotting techniques. 
Regulatory sequences for transcription and translation were constructed as overhangs of 
PCR primers, as well as the sequence to encode 6His and V5 epitope tag. PCR 
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reactions were 384-well PCR format, and 25% of randomly chosen PCR products from 
each plate were confirmed in 1.5% gel agarose electrophoresis. 
 
Figure 13. Protein microarray of human proteome. Three and a half thousand human 
proteins were expressed and arrayed directly onto two seperate glass slides. Newly 
expressed proteins were confirmed using antibody detection against N- and C- terminal 
fusion epitopes. 
The PCR products supplemented with 0.5 M betaine were spotted onto epoxy 
slides in volumes of 0.6 nL followed by spotting of 3.6 nL of cell-free expression lysate 
on top of every DNA spot. Immediately after finishing the spotting of the cell lysate, 
the slides were placed in the humidity chamber and  incubated for one hour at 37°C and 
removed to room temperature (28°C) for overnight incubation. On the next day, slides 
were stored in a slide box at –20°C minimum for three days before being used for the 
functional assay. Each expressed protein was detected by antibody recognizing fusion 
epitopes in the N- and C- termini. The antibodies were Alexa Fluor 647 conjugated-anti 
6His antibody and Cy3-conjugated anti V5 antibody. The quality of production was 
checked by statistical analysis by randomly choosing slides from one batch of the 
production (Fig. 14 and Fig 15). 
The success of protein expression was determined from the ratio of the 
foreground signal intensity from which the background was subtracted. The proteins 
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were considered to be expressed if the signal intensity was 1.5 times higher than the 
negative controls which contained primer dimer, spotting buffer, and cell-free 
expression lysate (Fig. 14a). Using this threshold, the success rate of full-length protein 
expression on the microarray was shown to be more than 90%. Some of the proteins 
could not be detected at their C-terminal tag since they did not pass the threshold limit 
which was defined as three times higher than the mean signal intensity of negative 
controls.  
 
Figure 14. Analysis of high-density protein microarrays. (a) High-density array 
representing 2030 different human proteins. (b) Log2 signal intensities of triplicate arrays, 
red box plot for N-terminal detection and green box plot for C-terminal detection. 
We compared the signal intensities of the N- and C-termini detections from 
interarray triplicates (Fig. 14b) using one-way ANOVA. There was no significant 
variantions between arrays of the same batch of production (p-values of 0.0026 and 
0.023, respectively). More than  99% of expressed  proteins can be replicated in all 
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array that were created at single time batch production. ANOVA analysis of N-termini 
detection indicates that most of expressed proteins were successful to be expressed 
among intearray replicates, but not with C-termini detection results. This result might 
be caused by incomplete translation or degradation of the nascent peptide 
 
Figure 15. Analysis of high-density protein microarrays. (a) Density plot of of N- and 
C-terminus detection. (b) Plot of full-length detected proteins against the protein size.  
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These results show that the difference in the levels of detected proteins between 
different arrays that were produced in one single batch is statistically significant. More 
than 99% of expressed proteins can be replicated in all array that were created at single 
time batch production. ANOVA analysis of  N-termini detection indicates that most of 
expressed proteins were successful to be expressed among intearray replicates, but not 
with C-termini detection results. This result might be caused by incomplete translation 
or degraded of newly synthesize protein. 
The signal detection of N- and C-terminus shows dissimilar distributions (Fig. 
15a). The C-teminal tag were often detected at lower value of intensities than N-
terminal tag. Pearson’s correlation between the protein size and intensities of full-length 
expressed proteins showed a moderate negative correlation (r = −0.46). A trend was 
shown in the plot of C-terminus intensity vs. protein size, bigger proteins had lower 
levels of expression (Fig. 15b). 
3.2.5 The autofluorescence of Green Fluorescent Protein (GFP) 
GFP was expressed and the emission of its autofluorescence was measured by 
direct scanning at 488 nm. We also compared this with purified recombinant GFP 
expressed in vivo. Purified recombinant GFP was also used to generate standard curves 
that were then used to semi-quantitatively determine the amount of expressed GFP on 
the microarray (Fig. 16). The estimated amount of expressed GFP on each spot was 
equal to 248 µg/mL of purified GFP. Up to the concentration of 500 ng/nL of spotted 
GFP did not show a saturation of mean signal intensity as well as with the expressed 
GFP. The fluorescence of GFP can be detected when it reaches the native stage 
condition [120]. We have shown that expressed protein on the microarray can retain its 
native function, in this case autofluorescence of GFP. 
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Figure 16. Autofluorescence of expressed GFP and standard GFP. (a) Array and signal 
intensity of expressed GFP, generated by detection of its autofluorescent emission. (b) Plot 
of autofluorescent emission of serial dilution standard GFP. 
3.2.6 Protein Microarrays for Binder and Antibody Selection 
Monoclonal antibodies were tested using high-density human protein microarrays. In 
addition, we also confirmed a pair of protein isoforms by antibodies and interaction of 
DARPin binders with their target proteins. To analyze antibody specificity we screened 
six tested antibodies from our collaboration partners within the Affinomics and six 
commercially available antibodies against human protein microarrays. These antibodies 
were validated using Western blot against purified recombinant antigen. The 
synthesized antigens for producing antibodies were included on the array as a control 
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for antibody detection. The expressed proteins were confirmed using both terminus 
detections. Antibody incubation was carried out on the array after being blocked by 
2% BSA in 1 PBST buffer for 1 hour. The antibody interactions were confirmed using 
Cy3-conjugated goat anti-human antibody. Primary antibodies were diluted to 1:1,000 
and secondary antibodies to 1:5,000 dilution. After washing 4 times with 1 PBST, 
every 5 min, slides were dried and scanned. 
Two of six tested antibodies on the protein microarrays demonstrated their 
binding with positive controls and expressed target proteins. These antibodies were 
created targeting IL6 (Tol40.8-H8) and MAPK1 (SH511-IIB1). However, only  
SH511-IIB1 showed mono-specificity to its target proteins. 
The antibody against MAPK1 (SH511-IIB1) showed strong interactions to its 
target peptide and target proteins on the array. Although, protein of MAP kinase 11 
showed very weak interaction with this antibody, but with another proteins it did not 
give any interaction. These findings confirmed the previous result that did not show 
cross-interactions between antibody SH511-IIB1 and other mitogen-activating kinase 
proteins.  
 
Figure 17. Antibody specificity by human protein microarray. The protein microarray 
was incubated with monoclonal anti-BCL2L1 and detected with Cy5-conjugated anti-
mouse antibody. Positional controls are Cy5-conjugated peptides. 
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Antibody against IL6 (TOL40.8-H8) gave many nonspecific interactions to most 
spotted control recombinant proteins as well as to proteins on the array. The antibody 
showed strong binding to its corresponding purified recombinant proteins that were 
used as positive controls of the interaction. TOL40.8-H8 showed strong binding to the 
expressed IL6 but also with many other proteins, proving poor selection of the antibody 
for its interaction partner. 
Three out of six commercially available antibodies gave either insensitive or  
non-specific for detection of target proteins on the arrays. For insensitive antibody 
increasing the antibody concentration and incubation time did not increase the detection 
signal. The monoclonal monoclonal anti-TP53, anti-CDK2 and anti-BCL2L1 antibodies 
exhibited strong signal intensities only in expressed of correspond proteins and 
displayed no cross reactivity with non-target proteins. The overall results of antibody 
screening was summarized in Table 2. 
RESULTS 
 
54 
 
Table 2. Selectivity and cross-reactivity of the selected antibodies 
Antibody name Protein target Positive control Target  
expressed proteins 
Nontarget 
expressed proteins 
ToL40.8-H8 IL6 +++ +++ yes 
SH511-IIB1 MAPK1 +++ +++ no 
SH473-IIIF7 PRKAR1A – – – – – – yes 
SH474-IIC12 PRKAR1B – – – – – – yes 
SH475-IID11 PRKAR2A – – – – – – yes 
SH476-IIIE4 PRKAR2B – – – – – – yes 
Monoclonal anti-TP53 antibody TP53 (a.a 94−202) N/A +++ no 
Monoclonal anti-CDK2 antibody CDK2 (a.a. 211-298) N/A +++ no 
Monoclonal anti-CFLAR antibody CFLAR (a.a 178−227) N/A --- yes 
Monoclonal anti-BCL2L1 antibody  BCL2L1(full length) N/A +++ no 
Anti-FLIP, N-terminal antibody CFLAR (a.a 2-18) N/A – – – yes 
Antibody 9A CYP1A1 and isoform2 +++ +++ no 
Antibody 9B CYP1A1 isoform2 +++ +++ no 
– – – = no/weak signal intensity; +++ = strong signal intensity
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Protein microarrays were used to validate the specific recognition of antibodies 
against protein isoforms. The antibodies have been tested before by Western blotting. 
One pair of the tested new antibodies can distinguish between two protein isoforms 
resulting from splicing variants of the coding sequence (Fig. 18a). The binding activity 
was confirmed on protein microarrays. 
 
Figure 18. Protein isoform-specific antibody and binder selection. (a) Twenty pairs of 
protein isoforms were expressed on microararys. The arrays were confirmed with terminal 
tag detection (i) and used for antibody selection. One antibody recognizes both isoforms 
(ii) and another is specific only to one isoform, the spots are indicated by white arrow (iii). 
White box indicates the negative controls (b) DARPin arrays for binder selection.  
(i) Two DARPin proteins were expressed and arrayed using MIST technology. (ii) Specific 
interaction between biotinylated MBP with DARPin_off7 (left) and false interaction of 
sfGFP with all proteins on the array. 
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The ankyrin repeat protein DARPin, as a high-affinity binder, was also tested to 
screen the specificity of the DARPin–protein construct. Two constructs of DARPin 
proteins were amplified and arrayed into protein microarrays with many replicates in 
one block using this technology. The in situ expressed proteins were confirmed using 
antibody against theit terminal epitopes. The arrays were incubated with two different 
binder proteins separately. Each protein was specific only to one DARPin protein. 
Maltose binding protein (MBP) showed a strong binding signal to DARP_off7. On the 
other hand, sfGFP did not show any specific interactions to DARPin_3G61 (Fig. 18b). 
3.2.7 Detection of PPI Using Protein Microarrays 
JUN-FOS interactions served as another model to be tested on protein microarrays. 
JUN and FOS proteins were expressed and arranged randomly on the array together 
with other proteins. The newly expressed proteins were confirmed by N- and 
C-terminal fusion epitope detection. All proteins on the arrays were fused with 6His 
and V5 epitope. The slides were blocked using phosphate saline buffer containing 
2% BSA and 20% glycerol. For the binding partner, JUN protein was fused with 6His 
and c-Myc epitope and expressed in vitro using the same expression system and 
purified with Ni-NTA agarose beads. The purified protein was checked using 
SDS-PAGE. The binding proteins were diluted in binding buffer and incubated to block 
the slide. After one hour of incubation, the slides were washed three times with binding 
buffer to remove unbound protein. Figure 18 shows the interactions of proteins were 
confirmed with Cy3-conjugated anti-c-Myc antibody. Controls were carried out with 
BSA and anti-cMyc antibody. 
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Figure 19. PPI detection by protein microarrays. C-terminus confirmation of expressed target protein on the array using Cy3-conjugated anti-V5 
antibody (upper-left array). The interactions of JUN-proteins were detected using anti-c-Myc antibody (upper-right array). The white and black arrows 
indicate the detection and the signal intensity of PPI, respectively. Plot of signal intensities of expressed proteins (blue), detection of JUN-proteins 
interactions (red) and control of detection (green). 
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4 DISCUSSION 
4.1  Generation of Surface-Bound DNA for Cell-Free Expression Templates 
The production of covalently bound DNA via polymerase reaction requires 
thermostable 5′ covalent attachment of primer molecules. As in DNA microarray 
technology, one of the most commonly used modifications for oligonucleotides is by 
primary amines at the 5′ or 3′ ends. The 5′-amino-modified oligonucleotides can 
directly be coupled onto the aldehyde and epoxy-coated glass surface to form covalent 
attachments. Amino-modified oligonucleotides covalently interacting with aldehyde-
modified glass slides were stabilized by dehydration to allow bond formation via Schiff 
base reaction. The reaction of epoxide with amine groups requires mild alkaline buffer 
conditions between pH 8–9 [101]. Therefore, the type of spotting buffer determines the 
success of direct covalent coupling of 5′ amino-modified oligonucleotides with epoxy 
groups of the surface. 
The success of primer immobilization on the slide surface is indicated by spot size 
and morphology [102]. The most suitable conditions in these studies were sodium 
phosphate buffer at pH 8.5 supplemented with 0.001% of nonionic detergent Tween-20 
(Fig. 4). The presence of nonionic and zwitterionic detergents has been reported to yield 
perfect quality of spots in terms of morphology, size, homogeneity, and signal 
reproducibility, as well as overall intensity [121]. This buffer gave uniform spot size 
and also showed dependency with the spotted volume and concentration of primers. 
The perfectly round spot morphology showed that the primers had been immobilized 
with the right combination of surface properties, spotting buffer, and working 
concentration. 
Then, for more quantitative comparison of spotting conditions, the experiment 
can be evaluated by direct or indirect detection of immobilized molecules. We used 
fluorescence-labeled probe hybridization for this purpose. With this method, the 
optimal number of molecules immobilized on the slide surface can be experimentally 
determined. Saturation can cause smearing near the spots or even across the entire slide 
surface. In most cases, however, extensive washing with buffer and finally with water 
can effectively reduce this effect. 
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The efficiency of primer immobilization is crucial for the subsequent steps of 
solid-phase PCR. The capacity of the surface area limits the number of molecules 
attaching to the active groups. For overall purposes of producing personalized protein 
microarrays, three types of molecules must be accommodated for: the primer, 
the solid-phase PCR product, and the expressed protein. The unreacted epoxy groups 
can be chemically deactivated or sealed by blocking agents. This blocking solution 
should not dissolve the spotted molecules. 
By applying previous experience with immobilization chemistry of 
oligonucleotides with active groups on surfaces we were able to obtain perfect primer 
spot morphology. Good quality of spot morphology is an indication that the primer 
molecules are evenly distributed in the spot. Thermostable covalent attachments were 
also optimized by simple adjustment of timing of immobilization. It has been reported 
that covalent attachment of 5′-thiol-modified primers to amino-modified glass slides 
using a heterobifunctional cross-linker is thermally more stable than other conjugate 
chemistry combinations [12]. With optimum primer concentration, stable covalent 
attachments of 5′-amino-modified primer will also produce optimum amount of bound 
DNA by solid-phase PCR (Fig. 5). The detachment of primers is essentially not due to 
the stability of covalent interactions between oligonucleotides and the active groups on 
the surface, but is also determined by the reaction system, i.e., buffer, additives, and 
humidity. Since covalent bonds are not entirely formed in solution, the coupling 
reactions took longer to complete. The optimum primer spotting conditions for 
solid-phase PCR are 5 µM primer and a coupling time of 24 h at 60–70% humidity, 
followed by dry storage for at least an additional 24 h. 
Choosing epoxy groups for surface chemistry has the dual advantage of providing 
direct covalent coupling of primers as well as the solid-phase PCR-generated DNA 
which are used for the generation of personalized protein microarrays. Epoxy groups 
can be deactivated by ethanolamine allowing for efficient solid-phase PCR as well as 
for fluorescent probe detection. One disadvantage of this treatment is poor 
immobilization of newly expressed proteins, however. An alternative of blocking 
method is to cover epoxy groups with inert molecules like BSA. BSA is known to 
compete with DNA polymerase for active adsorption on surfaces. Unfortunately, these 
blocking molecules can burry small-molecular probes that are used for DNA detection. 
In this case, both blocking methods were used in parallel. 
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Novel strategies for immobilizing DNA templates for in situ cell-free protein 
expression employ polymerases. PCR has been the main method for enriching copy 
numbers of DNA of interest [122]. DNA polymerase starts its activity whenever a short 
sequence of nucleotides has primed the replication process – these oligonucleotides are 
called primers. DNA polymerase only moves in the 5′-3′ direction, hence the 3′ end of 
the oligonucleotide primer must be free for DNA polymerase activity. Solid-phase PCR 
is also based on activity of DNA polymerase, to copy single-strand DNA into tethering 
primer which then generates the complementary strand. The most critical part for solid-
phase PCR is to have the 3′ end of the attached primer free in solution so that the DNA 
polymerase can elongate it. Using both upper and lower primers attached, this type of 
solid-phase PCR has been introduced as a bridge amplification [93]. Another solid-
phase PCR method allows one primer to diffuse freely in the PCR mix while the other 
is attached to the surface [12]. 
In this study, we attached both primers to the slide surface after solid-phase PCR 
has produced an inverse U-shape type of DNA product (Fig. 3a). The generated PCR 
products can be detected by various means, such as by cutting with restriction enzymes 
[98], fluorescent labeling of primers (only for single attached primer) [12], and probe 
hybridization [123]. In this study we used two different detection methods. First, with 
fluorescent-labeled probe detection of bound DNA products the amount of PCR 
products were interpreted based on the signal intensity of the fluorophore. We detected 
both strands of PCR products using a pair of probes (Fig. 6). With this detection 
method we ensured that the PCR products are double-strand DNA. The alternative 
detection method used second primer pairs, running a second PCR. The PCR mix 
contains all PCR components but minus DNA template, generating the PCR products in 
solution. By electrophoresis one can tell whether the DNA product is complete or not. 
By these means we have been able to produce bound DNA on epoxy slide surfaces by 
solid-phase PCR with sizes up to 3 kb. 
4.2  Cell-Free Expression of Personalized Protein Microarrays 
The procedure of immobilizing DNA produced by solid-phase PCR supports efficient 
transcription and translation processes. Linear and circular DNA templates have been 
routinely used for producing cell-free-based protein microarrays [11,78]. To our 
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knowledge, solid-phase PCR has not yet been used for producing protein microarrays. 
A recent application reports the production of mRNA immobilized on a slide surface 
[117]. Using solid-phase PCR, the immobilized primer can generate bound cDNAs on 
the chip surface that can be subsequently expressed into personalized protein 
microarrays. The particular conformation of the DNA will determine the eventual 
success of protein expression. The critical step is the removal of excess PCR mixture 
after solid-phase PCR, which can be achieved by washing; this should not denaturize 
the DNA. Salt buffer has been used for post-hybridization washing in DNA 
microarrays, both HEPES and SSC are suitable for this purpose [124]. After proper 
washing, the DNA array can be stored dry for some time or subsequently expressed in 
MIST by placing cell-free mixture on top of each spot of bound DNA [11]. 
We have generated covalently bound DNA arrays encoding human proteins on 
epoxy slide surface by solid-phase PCR and expressing them by the MIST method 
(Fig. 8). DNA encoding CREB3L1, TP53, MAPK1, and DIABLO was synthesized on 
the slide surface and subsequently used for in situ cell-free expression. All protein were 
fused at their N-terminal to 6His, and their C-terminal to V5 epitope tag. Using anti-
6His and anti-V5 antibodies which recognize the fused N- and C-terminal tags, 
respectively, in each coding sequence, we were able to confirm full-length expressed 
proteins. Terminal epitope tags can be easily replaced with other epitope tags in 
designing primers for DNA template construction. The system can also be adjusted for 
eukaryotic expression, as, e.g., rabbit reticulocytes, insect cells, and wheat germ cells by 
changing the regulatory elements in the primer sequences. 
We were able to express a multiple number of proteins on microarrays at the same 
time, leading up to personalized protein microarrays. To use the optimized construction 
of the immobilized primers that had worked successfully under our solid-phase PCR 
conditions, we did not change the key elements of the immobilized primers, i.e., spacer, 
linker, and common sequences. Production of multiple bound cDNAs on the surface 
required highly specific primer pairs, since we were to perform multiplex solid-phase 
PCR (Fig. 7). We added unique 5′ ends for each DNA target, through adapter-mediated 
primers by standard PCR. Thus, it was easier in setting a uniform Tm during solid-phase 
PCR. With uniform Tm, primer annealing can be easily controlled and nonspecific PCR 
products can be avoided. 
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The expressed protein on the chip was accessible across both terminus sites 
(Fig. 8). C-terminus detection indicated that translation was complete, yielding the full-
length expressed protein. The protein–antibody interactions revealed that the in situ 
expressed proteins obtained directly from covalently bound double-strand cDNA at the 
5′ end were able to interact with the protein-specific antibodies (Fig. 9). We could 
prove the success of the personalized protein microarrays by expressing DIABLO, 
CFLAR, TP53, AKT1, MAPK1, BCL2L1, and CDK2 from their cDNA products. The 
success rate of expression varied between these proteins. Negative spots yielded signals 
in the background range. Two of the expressed proteins were also confirmed by means 
of protein-specific antibodies (Fig. 9c, d). 
This novel protein microarray offers advanced strategies in personalized 
proteomics, reflecting the protein content of particular tissues of an individual. The 
array can be used for basic analysis of protein interactions with other proteins, DNA, 
RNA, or small molecules. The overall objectives of our efforts have been in detecting 
disease-specific protein isoforms (caused by mutation, polymorphisms, and splice 
variants), developing personalized diagnosis methods, and identifying compounds 
relevant for therapy. 
4.3  High-Density Protein Microarrays and Their Application 
We produced high-density protein microarrays by MIST with unpurified PCR products 
as DNA templates. Unpurified PCR products had no apparent disadvantage in terms of 
yield of expressed proteins and their following detection (Fig. 10). All PCR 
components were added at concentrations which do not inhibit cell-free expression 
[125]. The PCR purification buffer or kit was designed to clean the DNA from PCR 
residues by removing side products of sizes below 100 bp, with the exception of the 
particular system for purifying small fragment PCR products [119]. With long primers 
for DNA template construction (129- and 87mer) the available PCR purification system 
is not labor efficient. 
We compared Ni-NTA and epoxy slides in the production of protein microarrays. 
The expressed proteins were fused with N-terminal 6His tags and C-terminal V5 tags. 
When His-tagged proteins are immobilized on Ni-NTA, each bivalent Ni ion forms a 
complex with two His residues. Protein-fused N-terminal 6His tags provide a specific 
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site for oriented immobilization. Enzymatic studies showed that proteins fused with 
6His and thus becoming attached in control orientation to the solid surface had 
comparable activities as free proteins in solution [126]. However, the drawback of this 
protein immobilization approach is the low affinity of the His-tag to the Ni-NTA 
complex (K = 10
7 
M
–1
) causing unwanted dissociation of immobilized proteins [127]. 
We found the same to be the case for our production of protein microarrays. Protein 
spots tend to present a comet-tail effect that affected the spot morphology of 
microarrays. Ni-NTA surfaces gave higher background than epoxy surfaces (Fig. 11b). 
Until now, protein microarrays based on site-specific immobilization of His-tag 
proteins on Ni-NTA slides have been reported only by Zhu and coworkers [12]. Salts 
and certain common chemicals in protein-binding buffers can affect the stability of 
protein binding to Ni-NTA surfaces [38,80]. 
Epoxy slides immobilized proteins via randomly covalent interactions with 
primary amino groups in the protein structure. The interaction of proteins with the 
epoxy surface can be mediated by primary amino groups at N-termini or lysine residues 
that mostly are located at the surface of proteins [127]. The first protein microarrays 
were successfully produced by immobilizing proteins onto aldehyde slides in random 
orientation of protein binding [7]. Little evidence is available to claim the presence of 
covalent attachments of proteins to epoxy slides. The formation of covalent coupling 
requires pH 8−9, which was not possible for the protein expression system. However, 
the spot morphology of expressed proteins on microarrays was satisfactory and the 
immobilized proteins could be used for the testing of protein interactions. Based on the 
result of terminal detection for expressed proteins, we found no difference between 
Ni-NTA and epoxy slides in terms of the amount of detected proteins on the slides 
(Fig. 11c). Random or control orientation for the binding of proteins to the surface gave 
similar detection yields of expressed proteins. 
With careful adjustment of spotter pin capacity, high-density protein microarrays 
can be multiplexed without losing the consistency of protein expression across the 
arrays (Fig. 12). The CV of expressed GFP on the array was between 11 to 13%. This 
value indicated a slight variability in GFP yield per spot on the array. However, it 
should be noted that the amount of DNA template was not quantitatively equal, since 
we used unpurified PCR products. The previous report showed the average CV of 
spotted proteins and antibodies on epoxy slides was 34% [118]. As a basic rule of 
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thumb for cell-free protein expression: the more DNA template, the more yield of 
expressed protein. Furthermore, we found that the spotting replication of cell-free 
mixture did not interfere on the amount of GFP expression. Our fabrication of high-
density protein microarrays yields consistent and satisfactory spot morphology which 
has been reproducible in each case. 
The high-density human protein microarrays showed similar array quality as GFP 
microarrays. In MIST protein microarrays, each spot serves as a microscopic 
compartment providing individual environments for protein expression. Any cross 
contamination to the neighboring spots due to dissolving or diffusing can be 
prevented [9]. The newly expressed proteins can be retained within their own spots 
either by using specific or nonspecific interactions to the slide surface. 
The characteristics of a protein determine whether it is detectable or not. For this work, 
proteins were immobilized through nonspecific orientation covalent binding onto the 
slide surface. This nonorientated position may also limit access of antibodies to the 
fused epitope tags. By means of high-density protein microarrays we were able to 
express over 3500 proteins (Fig. 13) with successful expression reaching 90%. 
We show that multiplexing of production does not affect the amount of expressed 
proteins on the microarrays (Fig. 14b). With the existing noncontact spotter available, 
in single batch productions we are able to produce 25 slides of high-density protein 
microarrays containing more than 2000 proteins on each slide. 
N-terminus signal intensities more frequently occurred in the lower range than  
C-termini, as detected in the red (Alexa Fluor 647 conjugated 6His antibody) and 
green (Cy3-conjugated V5 antibody) laser channels, respectively (Fig. 15a). The 
difference of signal detection might indicate incomplete protein translation. The results 
can be interpreted in several ways, however: firstly, the C-terminal region is much less 
accessible than the N-terminal region. It is also possible, and potentially likely, that the 
C-terminal region is not fully available for V5 antibody interaction. The type of 
conjugated fluorophore molecules can also be a relevant factor. Unfortunately the 
antibodies were conjugated with different types of dyes. The Alexa Fluor dyes were 
more resistant to photobleaching and more brightly fluorescent than the Cy dyes [128]. 
The range of the signal intensities of the expressed proteins differs depending on 
protein size (Fig. 15b). The protein size has moderate negative association with the 
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level of expressed protein on the array. The signal intensities of expressed protein was 
found to decrease moderately with the increase of protein size. The success of protein 
expression in the cell-free-based system may vary depending on the nature of the 
expressed proteins and the type and conditions of the applied expression system. 
Certain limitations arise from the prokaryotic origin of the S30 T7 protein expression 
system regarding the translation and folding of eukaryotic proteins, whether in vivo or 
in vitro [75]. While the E. coli system produces high yields of synthesized proteins as 
compared to rabbit, wheat, and PURE systems, the E. coli system has not been able to 
effectively express very large (>100 kDa) or very small (<5 kDa) proteins [76].  
A possible explanation is that small polypeptides with minor secondary structures tend 
to be rapidly degraded and that the generation of incomplete lengths of proteins is due 
to pausing of the E. coli ribosome [77]. 
Our in situ protein microarray method can be used in combination with any cell-
free expression system of interest. DNA template construction can be adjusted for 
prokaryotic or eukaryotic systems through the PCR reaction. There is no need for 
complicated template manipulation; any known or unknown cDNA sequence can be 
used to easily construct protein expression templates by PCR. All necessary elements 
for each lysate can be added to upper primers as well as lower primers. Eukaryotic 
proteins expressed in the E. coli system lack most post-translational modifications, of 
course. However, because our technology is an open system, it is possible to add 
modifying enzymes, to modify the DNA template construction, and even to change the 
cell-free expression system not limited to the E. coli system. Although not effective for 
producing in situ protein microarrays, the noncoupled cell-free expression system can 
also be used in the MIST method. 
The density of the proteins on the surface determines the limit of detection and 
the sensitivity [93]. The epoxysilane coating of the NEXTERION
®
 Slide E did not 
produce a saturated autofluorescence signal from spotted GFP at concentrations of up to 
500 ng/nL per spot, which is equivalent to ~ 6 pmol (Fig. 16), as well as for the 
expressed GFP. However, expressed GFP exhibited saturation signal intensities when 
detected by Alexa Fluor 647-conjugated anti 6His antibody. 
A systematic comparison of protein microarrays on epoxy surface and other tested 
slides such as those coated with PEG-epoxy, amine, and dendrimer showed similar 
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detection limits. The authors of that report also demonstrated that all tested surfaces 
exert saturation of mean signal intensities of spotted proteins and antibodies in the 
range of 22.5 fmol/spot [129]. 
The expressed GFP on the microarray can retain its autofluorescence function. 
The fluorophore is generated by a sequential mechanism in an autocatalytic process. 
No cofactors or enzymatic components are required. The residues Ser65, dehydroTyr66, 
and Gly67 of the GFP form the imidazolidone ring. The reaction is initiated by a rapid 
cyclization between Ser65 and Gly67 to form an imidazolin-5-one intermediate which 
is followed by a much slower rate-limiting oxygenation of the Tyr66 side chain by 
oxygen on a time scale of hours. Gly67 is required for formation of the fluorophore and 
no other amino acid can replace Gly in this role. Once produced, GFP is quite 
thermostable, though [120]. 
We have tested the expressed protein microarrays in protein–antibody and 
protein–protein interaction studies. High-density protein microarrays were shown to be 
useful for rapid screening of antibody specificity (Fig. 17). We have detected highly 
specific recognition of antibodies to their target proteins and of antibodies cross binding 
to nontarget proteins (Table 2). An antibody was made which recognizes denatured, 
linear proteins in Western blot, while flow cytometry, sandwich ELISA, and functional 
assays require antibodies that recognize the natural, folded shape of the proteins. 
Several commercially available monoclonal antibodies have been validated by Western 
blotting and immunohistochemistry. The antibodies can be designed against partial 
regions of the target proteins while antibodies also can recognize full-length proteins. 
Three of these antibodies gave consistent results with those indicated in the 
product information of the manufacturers. One of these is anti-BCL2L1 antibody, made 
to recognize full-length BCL2L1; using a similar concentration as that recommended 
for ELISA, this antibody was able to detect newly expressed BCL2L1 on our arrays. 
In the case for anti-TP53 antibodies, it was designed to recognize internal regions of 
amino acid sequences. The anti-CDK2 and and anti-CFLAR antibodies were designed 
to regonize C-terminal regions of the respective proteins. Anti-CFLAR antibody failed 
to recognize the expressed CFLAR, but anti-CDK2 antibody effectively bound the 
expressed CDK2 on the arrays. 
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One out of six tested antibodies from our collaboration partner bound exclusively 
to its target peptide antigen as well as to the expressed protein (MAPK1). The anti-
MAPK1 antibody showed no cross-reactivity with nontarget proteins. For the rest of 
tested antibodies, they are either insensitive or nonspecific for detection of target 
proteins on the arrays. 
We expressed two DARPins using MIST and tested for their interaction with 
target proteins (Fig. 18). As a binder, DARPin typically exhibits highly specific binding 
and high affinity to target proteins; in contrast with traditional antibodies this binder 
does not require disulfide bonds for its active conformation [130]. One out two of the 
tested DARPins showed strong binding to maltose-binding proteins (MBP), confirming 
a previous report on DARPin interactions [130]. Protein microarrays can be used as an 
alternative selection method of DARPin libraries. 
Lastly, protein microarrays have been used for protein dimer interactions such as 
JUN-JUN and JUN-FOS (Fig. 19). JUN in its native form is a homodimer complex in 
solution, and forms a more stable complex with FOS. The dimer formation is mediated 
by coiled-coil-like leucine zippers. JUN-FOS interacts with the activator protein-1 
(AP1) binding site and regulates gene transcription in response to extracellular signals 
[131]. With a suitable choice of protein-binding buffer, protein microarrays can be used 
for a rapid and high-throughput detection of protein interactions. Salts can disguise the 
electrostatic attractions [132]. Additional macromolecules as the crowding agents can 
simulate the intracellular conditions – for in vitro PPI detection this can be achieved by 
adding 60−70% glycerol, 10% PEG 12,000, or 7% Ficoll 70 [133]. 
CONCLUSION 
68 
 
5 CONCLUSION 
We have developed a new kind personalized protein microarrays for detecting 
protein interactions starting from surface-bound DNA templates obtained by 
solid-phase PCR. Our optimized conditions of spotting buffer, primer concentration, 
and immobilization time in solid-phase PCR have allowed for surface-bound DNA with 
sizes up to 3 kb. The PCR products were detected using a pair of probes to hybridize 
both strands of DNA and run another PCR using the second primer pairs as alternative 
detection method for confirming the full-length DNA. 
Multiplex amplification could be optimized by solid-phase PCR. By these means 
protein-encoding DNA was copied from cDNA products and bound to the slide surface. 
Then, the arrayed DNA was expressed using a cell-free system to yield proteins on the 
array. Personalized protein microarray technology thus yields cell/tissue-specific, 
full-length proteins from cDNA/RNA. The expressed proteins on the chip can be 
confirmed by both terminal sites using antibodies corresponding to the fused tag. 
C-terminus detection was able to show that the in situ transcription and translation 
processes were complete. In situ expressed proteins obtained directly from covalently 
bound double-strand cDNA at the 5′ ends were able to interact with the specific protein 
antibodies, as shown by protein–antibody interactions. We conclude that personalized 
protein microarrays yield full-length expressed proteins with conformations adequate 
for specific protein–antibody interactions. 
The MIST technology has been optimized to produce high-density protein 
microarrays of a total of 3500 human proteins. The array quality was proven to be 
excellent in terms of technical usability, variability of the involved template 
preparation, protein expression conditions, and detection methods. Our protein 
microarrays can thus be of great value i) in screening for antibody specificity, ii) in 
DARPin arrays for selective target binding, and iii) for model studies of protein–protein 
interactions.  
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APPENDIX 
List of Primers 
Unmodified 
Gene Primer name Sequence 5′3′ 
AKT1 FOPU4_AKT1 tccgaacattggactggcacgggtaatacgactcactatagggagaccacaacggtttccctctagaaataattaggagatatacctaatgcatcatcat
catcatcatgctcccctcaacaacttctc 
AKT1 ROPU4_AKT1 ctgttggtccgatgccacttgcgttattacgtagaatcgagaccgaggagagggttagggataggcttaccgtcatcttggtcaggtggtgt 
ATF3 Fow_ATF3 cttcaacacccaggccag 
ATF3 Rev_ATF3 ctgcaatgttccttcttttatct 
BCL2L1 Fow_BCL2L1 tctcagagcaaccgggag 
BCL2L1 Rev_BCL2L1 ccgactgaagagtgagcc 
BCL2L1 FOPU1_BCL2L1 tcatggaaccgtactcgccgtgtaatacgactcactatagggagaccacaacggtttccctctagaaataattaggagatatacctaatgcatcatcatca
tcatcattctcagagcaaccgggagct 
BCL2L1 ROPU1_BCL2L1 ctggcgtagagtcgcatccagtcttattacgtagaatcgagaccgaggagagggttagggataggcttaccccgactgaagagtgagcccag 
CASP7 Fow_CASP7 gcagatgagcagggctg 
CASP7 Rev_CASP7 ttgactgaagtagagttccttgg 
CASP7 Fow_CASP7 gcagatgaacagggctg 
CASP7 Rev_CASP7 ttgactgaagtagagttccttgg 
CDK2 FOPU7_CDK2 tcccagtcaacactggaggctcgtaatacgactcactatagggagaccacaacggtttccctctagaaataattaggagatatacctaatgcatcatcatc
atcatcatagaaacaagttgacgggagag 
CDK2 ROPU7_CDK2 ctgagtgagacgctcgagtagcattattacgtagaatcgagaccgaggagagggttagggataggcttaccatggggtactggcttggtc 
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CFLAR Fow_CFLAR tctgctgaagtcatccatca 
CFLAR Rev_CFLAR tgtgtaggagaggataagtttctt 
CFLAR FOPU2_CFLAR tcctaccctcgtggttgcgctaataatacgactcactatagggagaccacaacggtttccctctagaaataattaggagatatacctaatgcatcatcatc
atcatcattctgctgaagtcatccatcag 
CFLAR ROPU2_CFLAR ctgtagaccctgtcggctacggattattacgtagaatcgagaccgaggagagggttagggataggcttaccgtgctgcagccagacataata 
CLDN18 Fow_CLDN18 atgtccaccaccacatgc 
CLDN18 Rev_CLDN18 cacatagtcgtgcttggaag 
CLDN18 FOPU3_CLDN18tv2 tccgcgtcttatacggaaccgcgtaatacgactcactatagggagaccacaacggtttccctctagaaataattaggagatatacctaatgcatcatcatc
atcatcatgtgactgcctgtcagggcttg 
CLDN18 ROPU3_CLDN18tv2 ctgtatcgtagggccactcaggcttattacgtagaatcgagaccgaggagagggttagggataggcttaccgtcgtgcttggaaggataagattg 
DARPin Fow_6HisDARPin tcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattagccaccatggtaagaaggagatataccatgactatga
gaggatcgcatcac  
DARPin Rev_V5DARPin ctggaattcgcccttttattacgtagaatcgagaccgaggagagggttagggataggcttaccattaagcttttgcaggatttc 
DARpin Fow_DARpin actatgagaggatcgcatcac 
DIABLO FOPU6_DIABLO tcccgatctgggaggtatggctttaatacgactcactatagggagaccacaacggtttccctctagaaataattaggagatatacctaatgcatcatcatc
atcatcatttgtgtgttcctgttgtggc 
DIABLO ROPU6_DIABLO ctgcccatcggaatcgagtgtggttattacgtagaatcgagaccgaggagagggttagggataggcttacctttctgacggagctcttctatc 
MAPK1 FOPU5_MAPK1 tccgaccttggcagtcgctaacgtaatacgactcactatagggagaccacaacggtttccctctagaaataattaggagatatacctaatgcatcatcatc
atcatcatgagatggtccgcgggcagg  
MAPK1 ROPU5_MAPK1 ctggggatgaacggctatcgcagttattacgtagaatcgagaccgaggagagggttagggataggcttaccgggctcgtcactcgggtcgtaata 
MCL1 Fow_MCL1 aacgcggtaatcggactc 
MCL1 Rev_MCL1 tcttattagatatgccaaaccag 
MDM2 Fow_MDM2 gtgaggagcaggcaaatg 
MDM2 Rev_MDM2 ggggaaataagttagcacaat 
MDM2 Fow_6His_MDM2 tcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattagccaccatggtaagaaggagatataccatgcatcatc
atcatcatcatgtgaggagcaggcaaatg 
APPENDIX 
79 
 
MDM2 Rev_V5_MDM2 ctggaattcgcccttttattacgtagaatcgagaccgaggagagggttagggataggcttaccggggaaataagttagcacaat 
MDM2 Rev_Myc_MDM2 ctggaattcgcccttttattacagatcctcttcagagatgagtttctgctcggggaaataagttagcacaat 
MDM2 Fow_MDM2_ovh aaagcaggctccaccatggtgaggagcaggcaaatg 
MDM2 Rev_MDM2_ovh ggggaaataagttagcacaataactttgtacaagaaagctgggtc 
pDON221, human cDNA Rev_fullV5 ctggaattcgcccttttattacgtagaatcgagaccgaggagagggttagggataggcttaccaactttgtacaagaaagctgggtc  
pDON221, human cDNA Fow_full6His tcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattagccaccatggtaagaaggagatataccatgcatcatc
atcatcatcataaagcaggctccaccatg  
pDON221, human cDNA Fow_full/Fow_full6His attaatacgactcactatagggagaccacaacggtttccctctagaaataattagccaccatggtaagaaggagatataccatgcatcatcatcatcatc
ataaagcaggctccaccatg 
pDON221, human cDNA Fow_full/Fow_fullNoTag attaatacgactcactatagggagaccacaacggtttccctctagaaataattagccaccatggtaagaaggagatataccatgaaagcaggctccaccatg 
pDON221, human cDNA Fow_fullNoHis tcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaagaaggagatataccatgaaagcag
gctccaccatg 
pDON221, human cDNA Rev_full6xHis ctggaattcgcccttttattaatgatgatgatgatgatgaactttgtacaagaaagctgggtc 
pDON221, human cDNA Rev_fullV5 ctggaattcgcccttttattacgtagaatcgagaccgaggagagggttagggataggcttaccaactttgtacaagaaagctgggtc 
pDON221, human cDNA Rev_full_Myc ctggaattcgcccttttattacagatcctcttcagagatgagtttctgctcaactttgtacaagaaagctgggtc 
piVEX, wtGFP Fow_full6His_GFP tcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattagccaccatggtaagaaggagatataccatgcatcatc
atcatcatcatttaagaaggagatataccatg 
piVEX, wtGFP Rev_fullV5_GFP ctggaattcgcccttttattacgtagaatcgagaccgaggagagggttagggataggcttaccatgatgatgatgatgagaac 
PPM1A Fow_PPM1A ggagcatttttagacaagcc 
PPM1A Rev_PPM1A ccacatatcatctgttgatgtaga 
Rev_DARpin Rev_DARpin attaagcttttgcaggatttc 
SMAD2 Seq_revSMAD2 cagacttttcactgctttc 
SMAD2 Seq_fowSMAD2 cagcagtgtaattaatacgac 
SMAD Seq_revSMAD2 order tgggatacctggagacgac 
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Amino-modified 
Target Primer name Sequence NH3-C6 5′3′ 
ConstSMAD2 Sld_Fow6His_SMAD2sp ttttttttttcagcagtgtaattaatacgactcactatagggagaccacaacggtttccctctagaaataattagccaccatggtaagaaggagatata
ccatgcatcatcatcatcatcattccatcttgccattcacg 
ConstSMAD2 Sld_FownoTag_SMAD2sp ttttttttttcagcagtgtacagatggtgatgatgattaatacgactcactatagggagaccacaacggtttccctctagaaataattagccaccatggt
aagaaggagatataccatgtccatcttgccattcacg 
CosntSMAD2 Sld_RevV5_SMAD2sp tttttttttttgccacttaccccacaaccagacgctggaattcgcccttttattacgtagaatcgagaccgaggagagggttagggataggcttaccgct
tgagcaacgcactg 
ConstpDON,human cDNA Solid FowpDON ttttttttttaggtgcgtgtgggttggatctcccgcgaaattaatacg 
ConstpDON,human cDNA Solid RevpDON ttttttttttgattagaaagtaacctcagtctggaattcgcccttttatta 
ConstU1 Sfow_U1 ttttttttttagatgcatgtgagttagatcatggaaccgtactcgccgtg 
ConstU1 Srev_U1 ttttttttttgattagaaagtaacctcagtgcgtagagtcgcatccagtc 
ConstU2 Sfow_U2 ttttttttttagatgcatgtgagttagatctaccctcgtggttgcgctaa 
ConstU2 Srev_U2 ttttttttttgattagaaagtaacctcagttagaccctgtcggctacgga 
ConstU3 Sfow_U3 ttttttttttaggtgcgtgtgggttggatcgcgtcttatacggaaccgcg 
ConstU3 Srev_U3 ttttttttttgattagaaagtaacctcagttatcgtagggccactcaggc 
ConstU4 Sfow_U4 ttttttttttagatgcatgtgagttagatcgaacattggactggcacggg 
ConstU4 Srev_U4 ttttttttttgattagaaagtaacctcagtttggtccgatgccacttgcg 
ConstU5 Sfow_U5 ttttttttttagatgcatgtgagttagatcgaccttggcagtcgctaacg 
ConstU5 Srev_U5 ttttttttttgattagaaagtaacctcagtgggatgaacggctatcgcag 
ConstU6 Sfow_U6 ttttttttttagatgcatgtgagttagatccgatctgggaggtatggctt 
ConstU6 Srev_U6 ttttttttttgattagaaagtaacctcagtcccatcggaatcgagtgtgg 
ConstU7 Sfow_U7 ttttttttttagatgcatgtgagttagatccagtcaacactggaggctcg 
ConstU7 Srev_U7 ttttttttttgattagaaagtaacctcagtagtgagacgctcgagtagca 
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Fluorophore-modified 
Gene Probe name Sequence Cy3/Cy5 5′3′ 
ILR1RN prbn_revILR1RN cgagaacagaaagcaggacaagcgct 
ILR1RN prbn_fowILR1RN gcacatcttccctccatggattcccaag 
CYCS nprb_revCYCS caataagaacaaaggcatcatctggggaga 
CYCS nprb_fowCYCS aaagagaccatggagatttggcccagtc 
DIABLO nprb_revDIABLO tatcaaactggcgcagatcaggcctctata 
DIABLO nprb_fowDIABLO tcttcctcctctgaattcattttcccaagt 
CHMP2A nprb_revCHMP2A ctcaagtccaacaactcgatggcacaagc 
CHMP2A nprb_fowCHMP2A accaagtcttttgccatgatgcgaacagc 
GFP nprb_revGFP actacaagacacgtgctgaagtcaagtttg 
GFP nprb_fowGFP ataagagaaagtagtgacaagtgttggcca 
SORT1 nprb_fowSORT1 tgttgtctgatccccatttggccaaac 
SORT1 nprb_revSORT1 agattatgaagatggctgcattttgggctaca 
SORT1 prb_fowSORT1 gtttggccaaatggggatcagacaaca 
SORT1 prb_revSORT1 tgtagcccaaaatgcagccatcttcataatct 
ICAM3 nprb_fowICAM3 ggagagcgaggtgacagaggtgcagaaag 
ICAM3 nprb_revICAM3 ccacgagcacatcatcaagtacaagggc 
ICAM3 prb_fowICAM3 ctttctgcacctctgtcacctcgctctcc 
ICAM3 prb_revICAM3 gcccttgtacttgatgatgtgctcgtgg 
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List of Genes 
76P ACTRT2 AKR1A1 ANXA5 ARHGAP1 ATP6AP1 
A4GALT ACVR1C AKR1B1 ANXA8L1 ARHGAP9 ATP6V0C 
AAAS ACY1 AKR1B10 ANXA9 ARHGDIA ATP6V0D1 
AARS ADA AKR1C2 AOAH ARHGDIB ATP6V1B2 
AASDHPPT ADAM2 AKR1C3 AP1S2 ARHGEF16 ATXN10 
AATF ADAM30 AKR1C4 AP2A1 ARHGEF2 ATXN7L1 
ABAT ADAM32 AKR7A2 AP2A2 ARHGEF5 AUH 
ABCB6 ADAMTS1 AKT1 AP2B1 ARIH2 AURKA 
ABCD1 ADAT1 ALB AP2M1 ARL1 AVPI1 
ABCD4 ADC ALDH1A1 AP3B1 ARL3 AXL 
ABCF2 ADCK4 ALDH1A2 AP3M1 ARL5A AZIN1 
ABCG2 ADFP ALDH3A2 AP3S1 ARL5B B2M 
ABHD11 ADH5 ALDH3B1 AP3S2 ARMCX1 B3GNT1 
ABHD5 ADMR ALDH3B2 AP4S1 ARMCX2 B3GNT2 
ABI2 ADORA1 ALDH4A1 APBB1 ARMCX3 B3GNT4 
ABI3 ADORA2B ALDH5A1 APEH ARNT2 B3GNT5 
ACAA1 ADORA3 ALDOA APEX1 ARPC1B B4GALT3 
ACAD8 ADRBK1 ALDOC APEX2 ARPM1 B4GALT7 
ACAD9 ADRM1 ALG1 API5 ARR3 BAALC 
ACADL ADSL ALG10 APLN ARRB2 BAAT 
ACADM AFP ALG12 APLP1 ARSA BACE1 
ACADS AGA ALG2 APOA1 ART3 BACE2 
ACO2 AGER ALG3 APOA2 ASAH1 BAD 
ACOT2 AGMAT ALG9 APOC3 ASB2 BAG3 
ACOT8 AGPAT2 ALKBH1 APOD ASB3 BAIAP2 
ACP2 AGPAT5 ALS2CR2 APOH ASCL1 BAK1 
ACPP AGT ALS2CR8 APOL2 ASGR1 BANK1 
ACSBG1 AGTR1 AMD1 APPBP1 ASGR2 BANP 
ACSBG2 AGTR2 AMY1A AQP1 ASNS BAP1 
ACSL4 AGTRAP ANAPC2 AQP2 ASPA BASP1 
ACSM3 AHCY ANGPTL7 AQP3 ASPSCR1 BAT1 
ACTA1 AHCYL1 ANKH AQP5 ATF3 BAT3 
ACTA2 AICDA ANKRA2 AQP9 ATF4 BAT4 
ACTB AIFM2 ANKRD1 ARAF ATG10 BAT5 
ACTC1 AIG1 ANKRD5 ARC ATG3 BBOX1 
ACTG2 AIPL1 ANKRD9 AREG ATG4C BBS2 
ACTN1 AK1 ANP32A ARF3 ATIC BBS4 
ACTN4 AK3 ANXA1 ARF4 ATOH7 BBS7 
ACTR10 AK3L1 ANXA11 ARF6 ATP4B BCAT2 
ACTR1A AK5 ANXA13 ARFGAP3 ATP5A1 BCHE 
ACTR1B AKAP10 ANXA2 ARFIP2 ATP5B BCKDK 
ACTR3B AKAP8L ANXA4 ARG1 ATP5G2 BCL2 
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BCL2A1 C11orf73 C6orf55 CASP4 CCNG2 CD81 
BCL2A1 C12orf24 C7orf36 CASP7 CCNH CD82 
BCL2L1 C12orf45 C7orf36 CASQ1 CCNI CD83 
BCL2L13 C14orf58 C8orf38 CASQ2 CCR6 CD84 
BCL7B C14orf94 C9orf116 CAST CCR7 CD86 
BCS1L C15orf43 C9orf156 CAV1 CCRL2 CD8A 
BDKRB2 C15orf48 C9orf71 CBFB CCS CD9 
BDNF C16orf33 C9orf80 CBLB CCT3 CD93 
BECN1 C16orf61 C9orf89 CBLC CCT5 CD99L2 
BET1 C18orf21 CA1 CBR1 CCT7 CDC20 
BFAR C18orf55 CA12 CBR3 CD160 CDC23 
BGLAP C19orf28 CA14 CBS CD164 CDC25A 
BGN C19orf43 CA2 CBX6 CD177 CDC27 
BHMT2 C19orf53 CA7 CCDC102A CD19 CDC34 
BIK C19orf6 CA9 CCDC104 CD1A CDC34 
BIRC2 C1orf128 CACNG4 CCDC107 CD2 CDC37 
BIRC4 C1orf162 CACNG6 CCDC110 CD200 CDC42 
BIRC7 C1orf182 CAGE1 CCDC120 CD207 CDC42EP1 
BLZF1 C1orf62 CALM2 CCDC120 CD24 CDC42EP2 
BMP7 C1orf76 CALML3 CCDC16 CD247 CDC42SE1 
BMPR1A C1QB CALN1 CCDC22 CD300C CDC45L 
BMX C1QBP CALR3 CCDC47 CD300LB CDC5L 
BNIP2 C1QBP CALU CCDC54 CD33 CDC6 
BOK C1QTNF1 CAMK1D CCDC72 CD34 CDCA4 
BOP1 C1QTNF2 CAMK1G CCDC86 CD36 CDCA5 
BPIL1 C1QTNF6 CAMK2D CCIN CD37 CDH13 
BRE C22orf28 CAMK2G CCKBR CD4 CDH15 
BTBD1 C2orf15 CAMK2G CCL11 CD40 CDH16 
BTBD14A C2orf18 CAMK4 CCL13 CD46 CDH18 
BTF3 C2orf30 CAMKK1 CCL19 CD47 CDIPT 
BTG1 C2orf4 CAMKK2 CCL2 CD48 CDK2 
BUB3 C2orf40 CAMKV CCL21 CD5 CDK2AP1 
BUD13 C2orf49 CAMP CCL22 CD52 CDK2AP2 
BXDC2 C2orf52 CANX CCL5 CD55 CDK4 
BYSL C3AR1 CAP1 CCNA1 CD59 CDK9 
BZW1 C3orf37 CAPG CCND1 CD5L CDK9 
BZW2 C4BPA CAPN1 CCND2 CD63 CDKN2C 
C10orf10 C4orf14 CAPN10 CCND3 CD68 CDKN2D 
C10orf33 C4orf22 CAPN6 CCNDBP1 CD69 CDR2 
C10orf63 C5AR1 CAPZA1 CCNE1 CD7 CDS2 
C11orf45 C5orf15 CASP2 CCNE2 CD7 CDSN 
C11orf64 C6 CASP3 CCNG1 CD74 CEACAM5 
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CEACAM8 CITED2 COG8 CPT1C CTGF CYP3A5 
CEBPG CKLF COIL CPXCR1 CTNNA1 CYP3A5 
CENPH CKM COL8A1 CRABP1 CTNS CYP4B1 
CENPK CKMT1A COL9A3 CRADD CTSA CYP4F11 
CES1 CKS1B COMMD9 CREB1 CTSD CYP4F12 
CES2 CKS1B COMT CREB3L1 CTSF CYP4X1 
CESK1 CLCC1 COPB1 CREG1 CTSG CYP51A1 
CETN1 CLCF1 COPE CRIP1 CTSH CYR61 
CFB CLCN7 COPS5 CRIP2 CTSK CYTL1 
CFHR1 CLDN1 COPS7A CRK CTSL D21S2056E 
CFHR2 CLDN10 COPZ2 CRMP1 CTSL2 DAD1 
CFLAR CLDN11 COQ2 CRSP9 CUGBP1 DAG1 
CFP CLDN14 COQ6 CRTAP CUL4B DAO 
CGB CLDN2 CORO1B CRTC1 CX3CL1 DAPP1 
CGREF1 CLDN8 CORO2B CRX CX3CR1 DARC 
CH25H CLDND2 COX10 CRYAB CXADR DARS 
CHEK1 CLEC1A COX11 CRYM CXCL1 DBP 
CHEK2 CLEC2B COX15 CRYZL1 CXCL10 DBR1 
CHEK2 CLEC3B COX4I1 CSDA CXCL11 DC2 
CHES1 CLEC4D COX5A CSF2RA CXCL5 DCAMKL2 
CHFR CLEC4M COX5B CSF3 CXCL6 DCBLD2 
CHGA CLGN COX6A1 CSH1 CXCR3 DCC1 
CHI3L1 CLIC1 COX6A2 CSK CXCR6 DCK 
CHI3L2 CLIC2 COX6B1 CSNK1A1L CXCR7 DCN 
CHIC2 CLIC3 COX6C CSNK1E CXorf20 DCP1A 
CHMP2A CLIC5 COX7A1 CSNK1E CXorf38 DCT 
CHMP5 CLPP COX7A2L CSNK1G2 CXXC1 DCTN3 
CHMP5 CLPTM1 COX7C CSNK2A1 CYB5A DCTN4 
CHN1 CLPTM1L CP110 CSNK2A2 CYB5D2 DDIT4 
CHODL CLSTN1 CPA1 CSNK2B CYB5R4 DDOST 
CHP CLU CPA2 CSRP2 CYBA DDT 
CHRAC1 CLUL1 CPA3 CSRP2BP CYBB DDX20 
CHRM1 CMPK CPA6 CSRP3 CYC1 DDX21 
CHRNA5 CNIH4 CPB1 CST3 CYCS DDX23 
CHRNB1 CNKSR1 CPE CST7 CYFIP1 DDX24 
CHST10 CNN3 CPEB3 CST9L CYP11A1 DDX39 
CHST12 CNOT10 CPM CSTB CYP1A1 DDX5 
CHST4 CNP CPN1 CSTF1 CYP20A1 DDX50 
CHST8 CNTFR CPNE1 CSTF2 CYP20A1 DDX56 
CIB1 CNTROB CPNE4 CTBP1 CYP2C8 DEFA1 
CILP COG1 CPNE6 CTCF CYP2J2 DENND1B 
CITED1 COG2 CPSF1 CTDSPL2 CYP2S1 DES 
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DXI DNMT3L E2F4 EIF3S6IP ERAF FAM13C1 
DGAT1 DNPEP EAF2 EIF3S7 ERAL1 FAM46D 
DGCR14 DNTT EBAG9 EIF3S8 ERCC1 FAM48A 
DGCR2 DOK2 EBI2 EIF4A1 ERCC3 FAM55C 
DGKA DOK4 EBP EIF4A2 ERCC5 FAM55D 
DHCR24 DOM3Z EBPL EIF4E ERCC8 FAM76B 
DHCR7 DPF2 ECD EIF4EBP1 EREG FAM83G 
DHDH DPH1 ECGF1 EIF4EBP2 ERRFI1 FAM84A 
DHFR DPP10 ECH1 EIF4ENIF1 ESAM FAM84A 
DHRS3 DPP3 ECM1 EIF4H ET FAM89B 
DHRSX DPP7 EDEM1 EIF5 ETF1 FANCC 
DHX16 DPP8 EDF1 EIF5A ETS2 FANCG 
DHX30 DPP9 EDG1 EIF5A2 ETV3 FAP 
DHX32 DPT EDG8 ELA3A ETV4 FARSLA 
DHX38 DRD1 EDN1 ELAC1 ETV5 FAS 
DHX40 DRD2 EDNRA ELAVL2 EVI1 FASLG 
DIABLO DRD5 EEF1A1 ELF1 EVI2B FASTK 
DIDO1 DRG1 EEF1A2 ELF2 EXOD1 FATE1 
DIMT1L DRG2 EEF1G ELF3 EXOSC3 FAU 
DIMT1L DSCR1 EEF2K ELF4 EXOSC8 FBL 
DIP13B DSCR1L1 EEFSEC ELF5 EXT1 FBLIM1 
DIRAS1 DSCR1L2 EFEMP1 ELK3 EXTL3 FBLN1 
DIRAS3 DSCR2 EFHC1 ELL2 EZH2 FBXL13 
DKC1 DSTN EFNA1 ELMO3 F11R FBXL2 
DKK1 DTX2 EFNA3 ELP4 F13A1 FBXL5 
DKK3 DTYMK EFNB1 EML1 F2R FBXO17 
DLAT DULLARD EFTUD2 EMP3 F2RL1 FBXO2 
DLL3 DUSP10 EHD2 ENC1 F3 FBXO5 
DLX3 DUSP11 EHD4 ENG F8A1 FBXW11 
DMAP1 DUSP12 EI24 ENO1 FABP1 FBXW2 
DMRTC1 DUSP13 EIF1 ENO2 FABP3 FCAR 
DNAJB1 DUSP14 EIF1AY ENO3 FABP5 FCER1A 
DNAJB11 DUSP14 EIF2A ENPP2 FABP7 FCGR2B 
DNAJB4 DUSP19 EIF2B2 ENPP4 FADS1 FCGRT 
DNAJB5 DUSP22 EIF2B5 ENTPD2 FADS3 FCN1 
DNAJB9 DUSP3 EIF2S1 ENTPD4 FAF1 FCN3 
DNAJC7 DUSP6 EIF2S2 EPB41L1 FAIM FCRL3 
DNASE1 DUT EIF2S3 EPB49 FAM103A1 FCRLA 
DNASE1L1 DVL3 EIF3S1 EPHA2 FAM107A FDFT1 
DNASE1L3 DYNLT1 EIF3S2 EPHX1 FAM122A FDPS 
DND1 DYRK1B EIF3S4 EPHX2 FAM126A FEM1C 
DNM1L DYRK4 EIF3S6 EPSTI1 FAM126B FES 
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FEV FNDC4 GAD1 GGTLA1 GNGT1 GPS2 
FEZ1 FNTB GADD45A GHRL GNL1 GPSM2 
FFAR3 FOLH1 GAGE1 GIF GNLY GPSN2 
FGD2 FOLR1 GAGE2 GIPC1 GNMT GPT 
FGF10 FOS GAL3ST1 GJA1 GNPTG GPX7 
FGF12 FOSB GALC GJA5 GOLGA7 GRAP 
FGF13 FOSL1 GALE GJB1 GORASP2 GRAP2 
FGF16 FOSL2 GALK2 GJB2 GOSR2 GRB10 
FGF18 FOXA2 GALNACT-2 GJB4 GOT2 GRB2 
FGF21 FPRL1 GALNT10 GK GP1BA GRB7 
FGF7 FRAT2 GALNT6 GK2 GP9 GRM3 
FGFR1 FRK GALNTL2 GK5 GPAA1 GRP 
FGFR1OP FRS3 GALNTL5 GKAP1 GPBAR1 GRPEL1 
FGFR4 FRZB GAP43 GLA GPBP1L1 GRWD1 
FGFRL1 FSCN1 GAPDH GLB1 GPC2 GSG1 
FHIT FSCN3 GAPDHS GLE1L GPC3 GSG1L 
FHL2 FSD1 GARS GLIPR1L1 GPC4 GSK3A 
FHL3 FST GAS7 GLIPR1L2 GPD1 GSK3B 
FHL3 FTH1 GATA2 GLRA3 GPHN GSS 
FHL5 FTL GBAS GLRB GPI GSTA2 
FKBP10 FTSJ3 GBL GLRX GPM6A GSTA3 
FKBP14 FUBP1 GBP1 GLTSCR2 GPM6B GSTA4 
FKBP2 FUK GBP5 GLUL GPNMB GSTM4 
FKBP3 FUS GCG GLYAT GPR114 GSTP1 
FKBP4 FUT11 GCH1 GM2A GPR135 GSTT1 
FKBP8 FUT4 GCK GMCL1L GPR146 GTF2A2 
FKBPL FUT9 GCLM GMDS GPR155 GTF2F1 
FKHL18 FXYD5 Gcom1 GMFB GPR157 GTF2H1 
FKRP FXYD6 GDF3 GMFG GPR161 GTF2H4 
FLAD1 FXYD7 GDI1 GMPPA GPR17 GTF2IRD1 
FLI1 FZD9 GDI2 GMPS GPR171 GTF3C5 
FLII G0S2 GDNF GNA13 GPR173 GTPBP3 
FLJ10324 G3BP1 GEM GNA14 GPR3 GTPBP8 
FLJ10815 G6PD GENX-3414 GNAI1 GPR30 GTSE1 
FLJ35773 GABARAPL1 GFI1 GNAI2 GPR34 GUCA1A 
FLOT1 GABARAPL2 GFPT2 GNAI3 GPR55 GUK1 
FLOT2 GABPB2 GFRA1 GNAT2 GPR65 GUSB 
FLRT3 GABRA3 GFRA3 GNB2L1 GPR84 GYG2 
FMO2 GABRA4 GGA2 GNB3 GPR89A GYLTL1B 
FMO3 GABRA5 GGCX GNG10 GPR92 GZMA 
FMO4 GABRB1 GGN GNG11 GPRC5B GZMH 
FMOD GABRG1 GGT1 GNG3 GPRC5C GZMK 
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H1F0 HIST3H3 HOXA5 ICAM2 IKZF5 ISL1 
H2AFV HK1 HOXA9 ICAM3 IL10 ISOC1 
H2AFZ HK2 HOXB13 ICAM4 IL10RA ISYNA1 
H3F3A HK3 HOXD1 ICMT IL10RB ITFG1 
HAAO HLA-B HOXD3 ICT1 IL11RA ITFG2 
HABP2 HLA-C HPCAL4 ID1 IL13RA1 ITGAX 
HACL1 HLA-DMB HPD ID2 IL13RA2 ITGB1 
HADH HLA-DOA HPN ID3 IL15 ITGB1BP1 
HADHA HLA-DOB HPRT1 IDH1 IL15RA ITGB2 
HADHB HLA-DPA1 HPS3 IDH2 IL17RA ITGB4BP 
HAGH HLA-DPB1 HRASLS3 IDH3A IL17RB ITGB5 
HAO2 HLA-DQA1 HRSP12 IDH3B IL18 ITGB7 
HAS1 HLA-DQB1 HSD17B2 IDH3B IL1A ITM2B 
HAVCR1 HLA-DRA HSD17B3 IER2 IL1B ITPA 
HBA1 HLA-E HSD17B4 IER3IP1 IL1F5 ITPK1 
HBB HLA-G HSD3B1 IFI16 IL1RN IVD 
HBG1 HLX1 HSD3B1 IFI27 IL21R IZUMO1 
HBZ HM13 HSF1 IFI30 IL24 JAGN1 
HCLS1 HMGB2 HSF4 IFI35 IL27RA JPH3 
HDAC1 HMGCL HSH2D IFIT1 IL2RB JUN 
HDAC3 HMGCR HSP90AB1 IFITM1 IL2RG JUNB 
HDGF2 HMGN1 HSPA1A IFITM2 IL6 JUP 
HEBP1 HMOX1 HSPA2 IFITM3 IL8 K-ALPHA-1 
HEMK1 HMOX1 HSPA5 IFNA2 IL8RA KARS 
HES1 HMOX2 HSPA8 IFNAR1 IL8RB KATNAL1 
HES4 HN1 HSPB1 IFNAR2 ILF2 KAZALD1 
HEXIM1 HN1 HSPB7 IFT57 ILK KBTBD10 
HGS HNF4G HSPB8 IGBP1 ILKAP KBTBD7 
HHLA2 HNMT HSPBAP1 IGF1R IMP4 KCMF1 
HIBADH HNRPD HSPBP1 IGF2 IMPDH2 KCNA3 
HIF1AN HNRPDL HSPC152 IGF2 INA KCNE1 
HIGD2A HNRPF HSPC171 IGFALS INHA KCNE1L 
HINT3 HNRPK HSPC171 IGFBP3 INHBA KCNE2 
HIST1H2AD HNRPR HSPE1 IGFBP6 INPP1 KCNG4 
HIST1H2AG HNRPU HSPH1 IGL@ INPP4A KCNIP3 
HIST1H2AK HOMER1 HTR1D IGL@ IPO11 KCNIP3 
HIST1H2AM HOMER2 HTR3A IGLL1 IQWD1 KCNJ10 
HIST1H3B HOMER3 HTRA2 IGSF4B IRAK4 KCNJ13 
HIST1H3E HOOK1 HTRA3 IGSF6 IRF1 KCNJ3 
HIST1H3F HOOK2 HYAL1 IGSF9 IRF3 KCNJ8 
HIST1H4H HOXA1 HYAL2 IHPK2 IRF4 KCNK1 
HIST2H2AA3 HOXA10 ICAM1 IKBKG ISCU KCNK13 
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KCNK17 KLK7 LCP1 LPXN MAL2 MCHR1 
KCNK6 KLRC1 LCP2 LRCH3 MALL MCL1 
KCNMB2 KLRC4 LDB1 LRCH4 MALT1 MCM3 
KCNN4 KLRD1 LDB2 LRFN3 MAN1B1 MCM7 
KCNS3 KLRG1 LDHA LRP12 MAN2B1 MCMDC1 
KCNV1 KNS2 LDLR LRRC29 MAOA MCOLN1 
KCTD13 KNTC2 LECT1 LRRC39 MAP1LC3A MDH2 
KCTD14 KPNA1 LENG1 LRRC59 MAP1LC3B MDK 
KCTD4 KPNA2 LENG1 LRRN5 MAP2K1IP1 ME3 
KDELC1 KPNA3 LENG8 LSAMP MAP2K2 MED28 
KDELR1 KPNA4 LEPROTL1 LSM2 MAP2K3 MED4 
KDELR2 KPNA6 LGALS1 LSM7 MAP2K5 MED6 
KDELR3 KPNB1 LGALS2 LSMD1 MAP2K6 MEST 
KEAP1 KRAS LGALS3 LSP1 MAP2K7 METAP2 
KEL KREMEN2 LGALS3BP LSS MAP3K14 METTL6 
KERA KRR1 LGALS8 LTA MAP3K7 MFAP1 
KHDRBS1 KRT10 LGI1 LTB4R MAP4K5 MFAP2 
KHDRBS3 KRT17 LGMN LTBR MAP7 MFN2 
KIF22 KRT18 LGR4 LTC4S MAPBPIP MFSD1 
KIF2A KRT20 LGTN LTF MAPK1 MGAT1 
KIF2C KRT23 LHFP LUM MAPK11 MGC29506 
KIF9 KRT33B LHFPL5 LY6H MAPK12 MGC33302 
KIFAP3 KRT5 LHX4 LYPD1 MAPK13 MGC34821 
KIFC3 KRT5 LIG4 LYPLA1 MAPK15 MGC35154 
KIR3DL1 KRT5 LILRA3 LYSMD2 MAPK3 MGC35361 
KISS1 KRT7 LILRB1 LYZ MAPK6 MGC39372 
KLC2 KRT8 LILRB3 M6PRBP1 MAPK9 MGC40069 
KLC4 KRTCAP2 LIN28 MAB21L1 MAPKAPK3 MGC40574 
KLF12 KSP37 LMAN1 MAD2L2 MAPRE2 MGC42105 
KLF15 L3MBTL2 LMBR1L MAGEA1 MAPRE3 MGC45491 
KLF4 LAD1 LMCD1 MAGEA10 MARCKSL1 MGC5139 
KLF5 LAIR1 LMO2 MAGEA2 MARCO MGC5139 
KLHDC2 LALBA LMO6 MAGEA3 MARK2 MGC7036 
KLHL1 LAMP1 LNX1 MAGEA6 MARK3 MGLL 
KLHL2 LAMP2 LOC200420 MAGEA9 MAT1A MGMT 
KLHL6 LANCL1 LOH12CR1 MAGEB1 MATR3 MGP 
KLK1 LASP1 LONP1 MAGEB4 MB MGST2 
KLK10 LASS4 LOXL2 MAGEC2 MBP MIF 
KLK2 LBP LOXL4 MAGED2 MC1R MIF4GD 
KLK3 LBR LPIN1 MAGEH1 MCEE MINK1 
KLK5 LCK LPL MAGOH MCF2L MIPEP 
KLK6 LCN2 LPPR2 MAL MCFD2 MIZF 
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MKI67IP MS4A4A NANS NFKBIB NRIP1 OSGEPL1 
MKNK1 MS4A6A NAP1L1 NFKBIL2 NRSN1 OSM 
MKRN2 MS4A7 NAP1L3 NFYB NSDHL OTX1 
MLANA MSH2 NAPSA NGB NSFL1C OXCT1 
MLF2 MSH4 NASP NGEF NSL1 OXCT2 
MLLT11 MSI2 NAT13 NGLY1 NSUN5 OXR1 
MMD MSL3L1 NAT5 NIF3L1 NT5C2 OXSR1 
MMP1 MSMB NCBP1 NIP30 NTF5 P2RX4 
MMP10 MSN NCBP2 NIP7 NUCKS1 P2RX7 
MMP2 MSX2 NCDN NIPA1 NUDT2 P2RY12 
MMP9 MT1A NCF1 NIT1 NUDT21 P2RY2 
MND1 MT1H NCF2 NIT2 NUDT3 P2RY6 
MOAP1 MT1M NCKAP1 NKG7 NUDT4 P4HA1 
MOBKL2B MT1X NCLN NKIRAS2 NUDT6 PA2G4 
MOCOS MT3 NCOA4 NKX2-5 NUP133 PABPC1 
MOCS3 MTAP NDRG1 NKX2-5 NUP54 PABPC3 
MOG MTCH2 NDUFA10 NME1 NUP62 PACSIN1 
MOG MTERF NDUFA3 NME6 NXF2 PACSIN3 
MORF4L1 MTHFD1 NDUFA6 NMNAT3 NXF3 PAF1 
MOSPD1 MTHFD2 NDUFB3 NMT2 OAS1 PAFAH2 
MOV10 MTMR9 NDUFB4 NMU OCLN PAGE1 
MOXD1 MUC7 NDUFB7 NMUR2 ODC1 PAGE4 
MPG MVD NDUFB8 NNMT OGG1 PAICS 
MPP1 MVK NDUFS2 NOC4L OGN PAK1IP1 
MPP2 MVP NDUFS3 NOL3 OGT PAK4 
MPP6 MX2 NDUFV1 NOLA1 OLFM2 PAK6 
MPST MXD1 NDUFV2 NOLC1 OLFML3 PAK7 
MPV17 MXD3 NEDD1 NOSTRIN OLIG1 PAMCI 
MPZ MYBL2 NEDD9 NOV OLR1 PAOX 
MRAS MYC NEFL NPC2 OMG PAPOLA 
MRAS MYCBP NEIL1 NPEPL1 OPRL1 PAPSS1 
MRCL3 MYF6 NEK3 NPEPL1 OPRS1 PAPSS2 
MRFAP1 MYL2 NEU1 NPLOC4 OPTN PAQR5 
MRP63 MYL6B NEUROD1 NPM1 OR2C3 PARD6A 
MRPL10 MYNN NEUROG1 NPPA OR51E2 PARL 
MRPL13 MYOC NF2 NPPB ORC2L PARP1 
MRPL17 MYOZ1 NFATC3 NPTX2 ORC5L PAX6 
MRPL28 MYST2 NFE2 NPY ORMDL1 PAX8 
MRPL40 NAGA NFE2L1 NPY1R OS9 PBK 
MRPS11 NAGK NFIB NQO1 OSBPL2 PCDHB14 
MRPS5 NALP12 NFIC NR4A1 OSCAR PCDHB5 
MS4A1 NALP2 NFIL3 NRBP1 OSGEP PCDHGC3 
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PCK1 PEX14 PIR PNKP PPP1R14A PRPH 
PCNA PEX19 PISD PNLIPRP2 PPP1R14C PRPS1 
PCNP PEX3 PITX2 PNOC PPP2R1A PRR14 
PCOLCE PEX5 PITX3 PNOC PPP2R1B PRRG4 
PCSK2 PEX7 PKD2L1 PNPLA4 PPP2R2B PRSS1 
PCSK4 PFKFB4 PKIA PNPLA8 PPP2R4 PRSS8 
PCSK5 PFKL PKNOX1 PODN PPP2R5A PRUNE 
PCSK7 PFKM PKP3 POLA2 PPP4C PSAP 
PCTK2 PFKP PLA2G12A POLD1 PPT1 PSAT1 
PCTK3 PFN1 PLA2G2A POLD2 PPY PSCD2 
PCYOX1 PGAM1 PLA2G3 POLI PPYR1 PSCD3 
PDCD10 PGCP PLA2G4D POLR2C PQBP1 PSEN2 
PDCD2 PGDS PLAC1 POLR2I PRAME PSENEN 
PDCD4 PGF PLAT POLR2J2 PRC1 PSG1 
PDCD5 PGLS PLAU POLR2K PRCP PSG9 
PDCD6 PGM1 PLAUR POLR2L PRDM4 PSMA1 
PDCL PGRMC1 PLCD4 POLR2L PRDX1 PSMA3 
PDE1A PGRMC2 PLCG2 POLR3D PRDX2 PSMA4 
PDE1B PGS1 PLEK POLR3F PRDX4 PSMA6 
PDE4A PHB PLEK POLR3K PRELP PSMA7 
PDE6B PHF1 PLEK2 POMC PREP PSMB2 
PDE6D PHF10 PLEKHA1 POMP PRG1 PSMB4 
PDGFRL PHF11 PLEKHA8 POP4 PRG2 PSMB6 
PDHA1 PHF17 PLEKHB2 PORCN PRKACG PSMC1 
PDHB PHF7 PLEKHF2 POT1 PRKAR1A PSMC3 
PDIA3 PHKA2 PLEKHO1 POU2AF1 PRKCDBP PSMC4 
PDIA4 PHYH PLK1 PPAP2B PRKCH PSMC5 
PDIA6 PHYH PLK2 PPARG PRKCZ PSMC6 
PDK1 PI3 PLK4 PPBP PRL PSMD12 
PDK4 PI4KII PLN PPCDC PRM1 PSMD13 
PDLIM5 PIAS2 PLS3 PPFIBP2 PRMT2 PSMD5 
PDLIM7 PIAS3 PLSCR1 PPIA PRMT5 PSME1 
PDPK1 PIAS4 PLSCR3 PPIB PRMT8 PSME2 
PEA15 PICK1 PLTP PPID PRNP PSME3 
PELO PIGF PMCH PPIH PROC PSTPIP1 
PENK PIGQ PMP2 PPIL1 PROCR PSTPIP2 
PEPD PIK3R3 PMP22 PPIL2 PROK1 PTDSS1 
PEPP-2 PIM2 PMP22 PPIL5 PROM1 PTDSS2 
PEX10 PIN1 PMPCB PPM1A PROS1 PTEN 
PEX11A PINK1 PMS2L3 PPM1G ProSAPiP1 PTGES2 
PEX11B PIP5K2C PMVK PPME1 PRPF19 PTGES3 
PEX12 PIPOX PNCK PPOX PRPF3 PTGFR 
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PTGS1 RAB9 RCN1 RNF182 RPS14 S100A11 
PTHLH RABAC1 RCVRN RNF183 RPS16 S100A16 
PTMA RABEPK RDBP RNF2 RPS17 S100A4 
PTMS RABGGTA REG3A RNF26 RPS2 S100A6 
PTP4A1 RABL2B REG4 RNF38 RPS20 S100A7 
PTPN1 RAC2 RENBP RNF40 RPS21 S100A8 
PTPN6 RAC3 REPS1 RNF6 RPS25 S100P 
PTPRA RACGAP1 RERG RNF7 RPS26 SAA1 
PTS RAD1 REXO4 RNF8 RPS28 SAA2 
PTTG1 RAD17 RFC3 RNPEP RPS29 SAE1 
PTTG1IP RAD18 RFC4 RNPS1 RPS3 SAMM50 
PUS1 RAD23B RFX2 RNUXA RPS3A SARS 
PUS3 RAD51L1 RFX4 RORC RPS4X SATB1 
PVR RAD51L3 RFX5 RP11-444E17.2 RPS4Y1 SC4MOL 
PVRL4 RAD54L2 RFXAP RPA2 RPS5 SCAMP3 
PWP1 RAG2 RGR RPL10 RPS6 SCAMP4 
PX19 RAMP1 RGS1 RPL10A RPS6KA1 SCARB2 
PYCR2 RAMP2 RGS13 RPL11 RPS6KA2 SCG5 
PYGB RAN RGS18 RPL13 RPS7 SCGB1A1 
PYGO2 RAPGEF3 RGS19 RPL14 RPS9 SCGB1A1 
QDPR RAPGEF4 RGS2 RPL17 RPSA SCGB3A2 
RAB11A RARA RGS5 RPL18 RPUSD1 SCHIP1 
RAB11B RARRES1 RGS5 RPL23 RRAD SCIN 
RAB11FIP5 RARRES2 RGS7 RPL24 RRAGC SCLY 
RAB13 RARRES3 RGS7 RPL26L1 RRAS SCMH1 
RAB1A RASD2 RHAG RPL28 RRM1 SCN2B 
RAB20 RASSF5 RHOBTB1 RPL31 RRM2 SCNM1 
RAB24 RB1 RHOC RPL32 RRP9 SCO1 
RAB27A RBBP4 RHOD RPL34 RSAD2 SCYE1 
RAB2B RBBP5 RHOH RPL35 RSPO3 SCYL3 
RAB30 RBBP7 RHPN2 RPL36 RSU1 SDC1 
RAB31 RBBP8 RICTOR RPL39 RTN4R SDC3 
RAB32 RBL1 RILP RPL4 RTP1 SDC4 
RAB34 RBM38 RIN1 RPL41 RTP4 SDCCAG3 
RAB35 RBM8A RLN1 RPL7A RUSC1 SDF2 
RAB38 RBMX RNASEH1 RPL9 RUTBC3 SDHD 
RAB3IL1 RBMY1F RNASEH2C RPLP0 RUVBL1 SDPR 
RAB4A RBP1 RND3 RPN2 RUVBL2 SDSL 
RAB5A RBP4 RNF10 RPP30 RWDD1 SEC22B 
RAB5B RBP5 RNF12 RPS10 RWDD2 SEC22C 
RAB7L1 RCBTB2 RNF125 RPS11 RYBP SEC23A 
RAB8A RCC1 RNF138 RPS13 S100A10 SEC23B 
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SEC24D SGCA SLC22A4 SLC6A13 SNUPN SSB 
SELL SGCB SLC22A5 SLC6A8 SNX1 SSBP1 
SELPLG SGCD SLC22A6 SLC7A3 SNX10 SSBP2 
SEMA3C SGCE SLC22A7 SLC7A4 SNX2 SSR3 
SEMA3D SH2D1A SLC22A8 SLC7A5 SNX4 SSR4 
SEMA4F SH2D1B SLC23A3 SLC7A7 SNX8 SSRP1 
SENP5 SH2D3A SLC25A1 SLC7A9 SNX9 SSTR1 
SENP8 SH3BGRL3 SLC25A1 SLCO3A1 SOAT1 SSTR2 
SEPHS1 SH3BP1 SLC25A10 SLCO4A1 SOCS3 SSU72 
SEPTIN4 SH3GL1 SLC25A11 SLCO6A1 SOCS5 SSX2IP 
SEPTIN9 SH3GL2 SLC25A13 SLFN5 SOD2 ST14 
SERF1A SH3GLB1 SLC25A15 SLPI SOD3 ST3GAL1 
SERF2 SH3KBP1 SLC25A16 SLU7 SORD ST5 
SERINC3 SH3PX3 SLC25A17 SMA3 SORT1 ST7 
SERPINA10 SHC3 SLC25A18 SMA3 SOX10 STAC 
SERPINA4 SHMT2 SLC25A19 SMAD1 SOX15 STAM2 
SERPINA5 SIAH1 SLC25A20 SMAD2 SP1 STAMBP 
SERPINA7 SIGIRR SLC25A22 SMAD2 SPAG6 STAR 
SERPINB2 SIGLEC9 SLC25A4 SMAF1 SPAM1 STAR 
SERPINB3 SIRT6 SLC27A3 SMARCAL1 SPANXB1 STARD3 
SERPINB4 SIRT7 SLC29A1 SMARCE1 SPARC STARD3NL 
SERPINB6 SKAP2 SLC2A3 SMC5 SPATA2 STAT3 
SERPINB9 SKIP SLC2A5 SMCP SPATA22 STAT4 
SERPIND1 SKP1A SLC2A6 SMN1 SPATA6 STAT5A 
SERPINE1 SLBP SLC2A8 SMO SPFH1 STAT5A 
SERPINE2 SLC12A4 SLC2A9 SMOC1 SPIN STATH 
SERPINF2 SLC13A3 SLC30A3 SMPDL3A SPINK2 STAU2 
SERPING1 SLC13A4 SLC31A1 SMTN SPINT1 STC1 
SERTAD1 SLC16A1 SLC31A2 SMU1 SPN STC2 
SERTAD4 SLC16A5 SLC33A1 SMYD3 SPOCK1 STIM1 
SESN2 SLC16A7 SLC35B2 SNAI1 SPOCK2 STK11 
SET SLC17A3 SLC38A2 SNAP23 SPP1 STK11IP 
SF3A1 SLC18A1 SLC38A5 SNAPC1 SPR STK17B 
SF3A2 SLC19A1 SLC39A1 SNCB SPTLC2 STK25 
SF3B4 SLC19A3 SLC39A7 SNCG SPZ1 STK32B 
SFMBT1 SLC1A1 SLC39A8 SND1 SQLE STK36 
SFN SLC1A4 SLC3A1 SNF1LK SQRDL STK38L 
SFRP4 SLC1A5 SLC40A1 SNN SRD5A1 STMN2 
SFRS2 SLC1A7 SLC44A5 SNRPA1 SRPK2 STMN3 
SFRS4 SLC20A1 SLC4A2 SNRPB2 SRPR STMN4 
SFTPD SLC20A2 SLC5A12 SNRPD2 SRrp35 STOM 
SFXN2 SLC22A15 SLC6A1 SNTA1 SS18 STOML2 
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STON1 TAGLN TGM4 TMEM153 TPI1 TRIP6 
STRA13 TAGLN2 THAP10 TMEM161B TPI1 TROVE2 
STRAP TAP1 THAP11 TMEM175 TPM1 TRPV1 
STRBP TARBP2 THAP3 TMEM31 TPM2 TRPV2 
STUB1 TBC1D2 THEG TMEM5 TPM4 TRPV6 
STX5 TBCB THEX1 TMEM66 TPP1 TRUB1 
STX6 TBL2 THRA TMEM8 TPSAB1 TRUB2 
STX8 TBRG4 THRA TMOD1 TPSAB1 TSEN34 
STXBP1 TBX3 THRAP4 TMPIT TPST1 TSG101 
STXBP6 TCAP THRAP5 TNF TPST1 TSGA10 
STYXL1 TCEAL1 THRAP6 TNFAIP1 TPTE TSPAN13 
SUFU TCEB1 THY1 TNFRSF10A TRA2A TSPAN31 
SUGT1 TCEB3 THY1 TNFRSF11B TRADD TSPAN4 
SULT1A1 TCF19 TIFA TNFRSF12A TRAF2 TSPAN5 
SULT2A1 TCL1A TIMM13 TNFRSF14 TRAF4 TSPAN6 
SULT4A1 TCN1 TIMM44 TNFRSF19L TRAF6 TSPAN7 
SUMO1 TCN2 TIMP1 TNFRSF21 TRAFD1 TSPYL1 
SUMO2 TCP1 TIMP3 TNFRSF9 TRAM1 TSSC1 
SUPT5H TCP11L2 TIMP4 TNFSF10 TRAM1L1 TSSK1 
SUPV3L1 TDRD7 TINF2 TNFSF13 TRAM2 TSSK3 
SURF1 TDRKH TIRAP TNFSF14 TRAP1 TSSK6 
SURF2 TEAD2 TITF1 TNIP1 TRAPPC1 TTC1 
SURF4 TEF TLE1 TNK1 TRAPPC2 TTC33 
SUSD3 TEKT1 TLK1 TNNC1 TRAPPC2 TTK 
SUV39H1 TEKT2 TLR2 TNNC2 TRAT1 TTL 
SUV39H2 TEKT3 TLR7 TNNI1 TREM1 TTLL1 
SYNGR2 Tenr TLX3 TNNI2 TREM2 TUBA1 
SYNGR3 TERF1 TLX3 TNNI3 TRIAP1 TUBA2 
SYT12 TESC TM4SF5 TNNT3 TRIM13 TUBA3 
SYT3 TESK1 TMBIM1 TOB1 TRIM13 TUBB 
SYTL1 TFAP2A TMC4 TOB2 TRIM14 TUBB2B 
TAC1 TFAP2B TMC6 TOLLIP TRIM22 TUBB2B 
TAC3 TFAP4 TMCO6 TOMM22 TRIM23 TUBB6 
TACSTD1 TFB1M TMED1 TOMM40 TRIM27 TUBE1 
TACSTD2 TFDP1 TMED2 TOMM70A TRIM31 TUBG1 
TAF11 TFF3 TMEFF1 TOR1A TRIM32 TUBGCP3 
TAF12 TFG TMEM115 TOR1B TRIM38 TUFT1 
TAF1A TFIP11 TMEM123 TOX TRIM44 TUSC3 
TAF1B TFPI2 TMEM126B TP53 TRIM7 TWF1 
TAF6 TFRC TMEM138 TPD52 TRIM74 TWF2 
TAF7 TGIF TMEM14C TPD52 TRIM8 TWIST1 
TAF9B TGIF2 TMEM15 TPD52L2 TRIP10 TWIST2 
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TXN2 USP2 WNT2 ZNF524 
   TXNDC1 USP3 WNT5B ZNF559 
   TXNDC12 USP30 WNT7A ZNF567 
   TXNDC5 USP33 WRNIP1 ZNF581 
   TXNL1 USP44 WWP2 ZNHIT1 
   TYROBP USP5 WWTR1 ZPBP 
   U2AF1L4 UTP14A XAB1 ZSCAN5 
   UBADC1 UXS1 XAB2 ZYX 
   UBAP1 VAMP5 XAGE2 
    UBD VCL XBP1 
    UBE1C VDAC1 XLKD1 
    UBE1L VDP XPA 
    UBE2A VEGFB XRCC3 
    UBE2B VEGFC XRCC5 
    UBE2C VEGFC YARS 
    UBE2D1 VHL YARS2 
    UBE2I VIL2 YBX1 
    UBE2J1 VILL YKT6 
    UBE2L6 VIPR2 YKT6 
    UBE2T VPREB3 YTHDF2 
    UBE2U VPS18 YWHAG 
    UBE2V2 VPS54 YWHAZ 
    UBOX5 VPS72 ZBTB44 
    UBXD2 VRK2 ZBTB48 
    UCHL1 VSIG4 ZBTB48 
    UCHL5IP VSNL1 ZCCHC17 
    UCN2 VTI1B ZCRB1 
    UCP2 VTN ZDHHC4 
    UFC1 WBP1 ZDHHC5 
    UGDH WBP11 ZDHHC7 
    UGT2B4 WBP2 ZFAND3 
    UGT2B7 WBSCR27 ZFP36L1 
    UNC45A WDR12 ZFP36L2 
    UQCRC2 WDR18 ZG16 
    URG4 WDR20 ZMYND11 
    UROD WDR4 ZMYND12 
    UROS WDR45 ZMYND19 
    USP10 WDR51B ZNF307 
    USP12 WDR57 ZNF350 
    USP13 WDR68 ZNF426 
    USP14 WFDC1 ZNF461 
    USP16 WIF1 ZNF496 
    
       
        
